0001558370-20-007863.txt : 20200708 0001558370-20-007863.hdr.sgml : 20200708 20200629190510 ACCESSION NUMBER: 0001558370-20-007863 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200629 DATE AS OF CHANGE: 20200629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hepion Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001583771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462783806 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36856 FILM NUMBER: 20998820 BUSINESS ADDRESS: STREET 1: 399 THORNALL STREET STREET 2: FIRST FLOOR CITY: EDISON STATE: NJ ZIP: 08837 BUSINESS PHONE: 732-902-4000 MAIL ADDRESS: STREET 1: 399 THORNALL STREET STREET 2: FIRST FLOOR CITY: EDISON STATE: NJ ZIP: 08837 FORMER COMPANY: FORMER CONFORMED NAME: ContraVir Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20130806 10-Q 1 hepa-20200331x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


(Mark One)
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 2020
Or

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission File Number 001-36856

HEPION PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)



Delaware (State or other jurisdiction of incorporation or organization)		46-2783806 (I.R.S. Employer Identification Number)

399 Thornall Street, First Floor Edison, New Jersey 08837 (Address of Principal Executive Offices)

(732) 902-4000

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	HEPA	The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.:


Large accelerated filer ☐	Accelerated filer ☐	Non-accelerated filer ☒	Smaller reporting company ☒	Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s Common Stock outstanding as of June 19, 2020 was 9,025,061.

Table of Contents

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q for Hepion Pharmaceuticals, Inc. may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, those discussed under Item 1A. Risk Factors and elsewhere in the audited condensed consolidated financial statements as of and for the year ended December 31, 2019 contained in the Company’s Annual Report on Form 10-K and 10-K/A filed with the Securities and Exchange Commission. These factors include the uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate safety and efficacy in larger-scale clinical trials, the risk that we will not obtain approval to market our products, the risks associated with dependence upon key personnel and the need for additional financing. We do not assume any obligation to update forward-looking statements as circumstances change and thus you should not unduly rely on these statements.Cautionary Note Regarding Forward-Looking Statements.

Statement Regarding COVID-19-Related Filing Delay

Hepion Pharmaceuticals, Inc. has relied on the U.S. Securities and Exchange Commission’s March 25, 2020, Order Rel. No. 34-88465 to postpone filing this Quarterly Report. The reasons for our postponement are set out fully in our May 14, 2020, Form 8-K, which is incorporated here by reference. In particular, COVID-19 has caused severe disruptions in travel and transportation and limited access to our facilities resulting in limited support from our staff.

Table of Contents

HEPION PHARMACEUTICALS, INC.

FORM 10-Q

TABLE OF CONTENTS


		Page
PART I—FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (unaudited):	3
	Condensed Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019	3
	Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2020 and 2019	4
	Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31, 2020 and 2019	5
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019	7
	Notes to Condensed Consolidated Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	32
Item 4.	Controls and Procedures	32

PART II—OTHER INFORMATION

Item 1A.	Risk Factors	34
Item 6.	Exhibits	34
SIGNATURES		35

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

HEPION PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)



	March 31,		December 31,
	2020		2019
Assets
Current assets:
Cash	$	16,047,669	$	13,922,972
Prepaid expenses		1,259,881		465,693
Total current assets		17,307,550		14,388,665
Property and equipment, net		48,445		57,166
Right-of-use assets		724,916		797,913
In-process research and development		3,190,000		3,190,000
Goodwill		1,870,924		1,870,924
Other assets		128,289		127,939
Total assets	$	23,270,124	$	20,432,607

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	850,066	$	491,557
Accrued expenses		412,842		493,636
Operating lease liabilities, current		273,093		266,696
Total current liabilities		1,536,001		1,251,889
Contingent consideration		2,460,000		2,430,000
Deferred tax liability		18,752		18,752
Operating lease liabilities, non-current		472,382		540,751
Derivative financial instruments, at estimated fair value—warrants		15,303		5,623
Total liabilities		4,502,438		4,247,015
Commitments and contingencies (Note 11)
Stockholders’ equity:
Series A convertible preferred stock, stated value $10 per share, 85,581 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively.		855,808		855,808
Series C convertible preferred stock, stated value $1,000 per share, 1,827 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively.		861,033		861,033
Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 6,074,122 and 3,760,255 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively.		606		375
Additional paid in capital		104,459,486		97,651,006
Accumulated deficit		(87,409,247)		(83,182,630)
Total stockholders’ equity		18,767,686		16,185,592
Total liabilities and stockholders’ equity	$	23,270,124	$	20,432,607

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)


	Three Months Ended
	March 31,
	2020		2019
Revenues	$	—	$	—
Costs and expenses:
Research and development		2,637,331		518,040
General and administrative		1,549,606		1,403,660
Total operating expenses		4,186,937		1,921,700
Loss from operations		(4,186,937)		(1,921,700)

Other income (expense):
Change in fair value of debt		—		(59,641)
Interest on debt		—		(98,287)
Change in fair value of derivative instruments—warrants and contingent consideration		(39,680)		95,917
Loss before income taxes		(4,226,617)		(1,983,711)
Income tax benefit		—		—
Net loss		(4,226,617)		(1,983,711)
Deemed dividend (see Note 5)		—		(24,321)
Net loss attributable to common shareholders	$	(4,226,617)	$	(2,008,032)

Weighted average common shares outstanding:
Basic and diluted		4,345,699		250,126

Net loss per common share: (see Note 10)
Basic and diluted	$	(0.97)	$	(8.03)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)



	Preferred Stock,			Preferred Stock,
	Series A			Series C			Common Stock,			Additional				Total
	$0.0001 par value			$0.0001 par value			$0.0001 par value			Paid in		Accumulated		Stockholders'
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Equity
Balance at December 31, 2019	85,581	$	855,808	1,827	$	861,033	3,760,255	$	375	$	97,651,006	$	(83,182,630)	$	16,185,592
Net loss	—		—	—		—	—		—		—		(4,226,617)		(4,226,617)
Stock-based compensation expense	—		—	—		—	—		—		8,246		—		8,246
Issuance of common stock, net	—		—	—		—	2,311,867		231		6,788,234		—		6,788,465
Warrant exercises	—		—	—		—	2,000		—		12,000		—		12,000
Balance at March 31, 2020	85,581	$	855,808	1,827	$	861,033	6,074,122	$	606	$	104,459,486	$	(87,409,247)	$	18,767,686

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)


	Preferred Stock,			Preferred Stock,
	Series A			Series C			Common Stock,			Additional				Total
	$0.0001 par value			$0.0001 par value			$0.0001 par value			Paid in		Accumulated		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Equity
Balance at December 31 2018	85,581	$	855,808	1,974	$	930,311	247,013	$	25	$	76,652,839	$	(76,463,932)	$	1,975,051
Net loss	—		—	—		—	—		—		—		(1,983,711)		(1,983,711)
Stock-based compensation expense	—		—	—		—	—		—		17,506		—		17,506
Conversion of preferred stock to common	—		—	(46)		(46,000)	424		—		46,000		—		—
Accretion of discount	—		—	—		24,321	—		—		(24,321)		—		—
Issuance of common stock, private placement	—		—	—		—	47,429		5		486,278		—		486,283
Issuance of common stock, debt redemption	—		—	—		—	11,882		1		149,917		—		149,918
Balance at March 31, 2019	85,581	$	855,808	1,928	$	908,632	306,748	$	31	$	77,328,219	$	(78,447,643)	$	645,047

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)



	Three Months Ended
	March 31,
	2020		2019
Cash flows from operating activities:
Net loss	$	(4,226,617)	$	(1,983,711)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		8,246		17,506
Depreciation and amortization		6,527		4,641
Change in fair value of derivative intstrument-warrants		9,680		(195,917)
Change in fair value of contingent consideration		30,000		100,000
Change in fair value of debt		—		59,641
Non-cash interest expense		—		23,906
Amortization of debt discount recorded as interest expense		—		69,516
Changes in operating assets and liabilities:
Accounts payable and accrued expenses		277,715		(46,188)
Prepaid expenses and other assets		(783,513)		(107,821)
Net cash used in operating activities		(4,677,962)		(2,058,427)

Cash flows from investing activities:
Purchase of property and equipment		—		(37,849)
Proceeds from disposal of property and equipment		2,194		—
Net cash provided by (used in) investing activities		2,194		(37,849)

Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs		6,788,465		—
Proceeds from the exercise of warrants		12,000		—
Proceeds from the issuance of short term debt and common stock		—		1,250,000
Repayment of debt financing		—		(303,547)
Net cash provided by financing activities		6,800,465		946,453
Net increase (decrease) in cash		2,124,697		(1,149,823)
Cash at beginning of period		13,922,972		2,832,429
Cash at end of period	$	16,047,669	$	1,682,606

Supplementary disclosure of cash flow information:
Cash paid for interest	$	—	$	8,953
Supplementary disclosure of non-cash financing activities:
Conversion of Series C convertible preferred stock (part of Series C deemed dividend)	$	—	$	46,000
Accretion of Series C preferred stock discount upon conversion		—		24,321
Issuance of common stock for debt redemption		—		126,094
Adoption of lease accounting		—		733,374

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Business Overview

Hepion Pharmaceuticals, Inc. (we, our, or us) is a biopharmaceutical company headquartered in Edison, New Jersey, focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (“HCC”) associated with non-alcoholic steatohepatitis (“NASH”), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 is a cyclophilin inhibitor that targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. CRV431 additionally shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease.

On July 18, 2019, we filed a certificate of amendment (the “Certificate of Amendment”) to our certificate of incorporation (the “Certificate”) to change our name from “ContraVir Pharmaceuticals, Inc.” to “Hepion Pharmaceuticals, Inc.” The name change became effective as of July 18, 2019.

We are developing CRV431 as our lead molecule. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. To date, in vitro and/or in vivo studies have demonstrated reductions in HBV DNA, HBsAg, HBeAg, inhibition of virus uptake (NTCP transport inhibition), and stimulation of innate immunity. Importantly, in vivo studies in a NASH model of fibrosis and HCC have repeatedly demonstrated CRV431 reduces fibrosis scores and overall liver tumor burden. Hence, CRV431 is a pleiotropic molecule that may not only treat liver disease but may also serve to reduce important risk factors (e.g., HBV) for developing the disease. We have completed a phase 1 study with CRV431 demonstrating safety, tolerability, and pharmacokinetics (PK).

CRV431

On May 10, 2018, we submitted an Investigational New Drug Application (“IND”) to the U.S. Food and Drug Administration (“FDA”) to support initiation of our CRV431 HBV clinical development program in the United States and received approval in June 2018. We completed the first segment of Phase 1 clinical activities for CRV431 in October 2018 wherein we reached a major clinical milestone of positive data from a Phase I trial of CRV431 in humans. This achievement triggered the first milestone payment, as stated in the Merger Agreement for the acquisition of Ciclofilin Pharmaceuticals, Inc. (“Ciclofilin”) and we paid a related milestone payment of $1,000,000 and issued 1,439 shares of our common stock with a fair value of $55,398, representing 2.5% of our issued and outstanding common stock as of June 2016, to the Ciclofilin shareholders.

On June 17, 2019, we submitted an IND to the FDA to support initiation of our CRV431 NASH clinical development program in the United States and received approval in July 2019.

2. Basis of Presentation and Going Concern

These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet as of December 31, 2019 was derived from the audited annual consolidated financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2019 contained in our Annual Report on Form 10-K.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Principles of Consolidation

The accompanying condensed consolidated financial statements include our accounts and the accounts of our subsidiaries, Contravir Research Inc. and Hepion Research Corp, which conduct their operations in Canada. All intercompany balances and transactions have been eliminated in consolidation.

Reverse Stock Split

On May 28, 2019, we effected a 1 for 70 reverse stock split of our common stock. The par value and the number of authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these financial statements have been adjusted retroactively to reflect the reverse stock split.

Going Concern

As of March 31, 2020, we had $16.0 million in cash, we had an accumulated deficit of $87.4 million, and we had working capital of $15.8 million. For the three months ended March 31, 2020, cash used in operating activities was $4.7 million and we had a net loss of $4.2 million. We have not generated revenue to date and have incurred substantial losses and negative cash flows from operations since our inception. We have historically funded our operations through issuances of convertible debt, common stock and preferred stock. We expect to continue to incur losses for the next several years as we expand our research, development and clinical trials of CRV431. We are unable to predict the extent of any future losses or when we will become profitable, if at all.

These condensed consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We will be required to raise additional capital within the next year to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct business. If we are unable to raise additional capital when required or on acceptable terms, we may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.

COVID-19 Pandemic

On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

operations. Management is actively monitoring the global situation and its impact on our financial condition, liquidity, operations, suppliers, industry, and workforce.

We may experience delays in the conduct of clinical testing of our product candidate. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. The COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidate. The evolving COVID-19 pandemic is also likely to directly or indirectly impact the pace of enrollment in our CRV431 clinical trials for at least the next several months and possibly longer as patients may avoid or may not be able to travel to healthcare facilities and physicians' offices unless due to a health emergency. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a clinical trial, in securing clinical trial agreements with prospective sites with acceptable terms, in obtaining institutional review board approval to conduct a clinical trial at a prospective site, in recruiting patients to participate in a clinical trial, related to the COVID-19 pandemic, or in obtaining sufficient supplies of clinical trial materials. Any delays in completing our clinical trials will increase our costs, slow down our product development, timeliness and approval process and delay our ability to generate revenue.

The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change and we do not yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. Although we cannot estimate the length or gravity of the impact of the COVID-19 outbreak nor estimate the potential impact to our fiscal year 2020 financial statements at this time, if the pandemic continues, it could have a material adverse effect on our results of future operations, financial position, liquidity, and capital resources, and those of the third parties on which we rely in fiscal year 2020.

On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), as amended on June 5, 2020 by the Paycheck Protection Program (“PPP”). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. On April 13, 2020, we were granted a loan (the “Loan”) from JPMorgan Chase Bank, N.A. in the aggregate amount of $176,585, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act. We are continuing to evaluate and examine the impacts the CARES Act may have on our business, results of operations, financial condition or liquidity.

The Loan, which was in the form of a Note dated April 13, 2020 issued by us, matures on April 13, 2022 and bears interest at a rate of 0.98% per annum, payable monthly commencing on November 13, 2020. The Note may be prepaid by us at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, rent and utilities. We intend to use the entire Loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. We intend to comply with the loan forgiveness provisions in the legislation; however, there can be no assurance that we will obtain full forgiveness of the loans based on the legislation.

3. Summary of Significant Accounting Policies

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Our significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2019 included in our Form 10-K. Since the date of such consolidated financial statements, there have been no changes to our significant accounting policies.

Cash

As of March 31, 2020 and December 31, 2019, cash was $16.0 million and $13.9 million, respectively, consisting of checking accounts held at U.S. and Canadian commercial banks. Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced losses related to these balances.

Fair Value of Financial Instruments

Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.

ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:

●	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.

●	Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.

●	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Financial instruments consist of cash and accounts payable, short-term debt, derivative instruments — warrants, convertible debt and contingent consideration. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short term nature, except for derivative instruments — warrants and contingent consideration, which were marked to market at the end of each reporting period. See Note 5 for additional information of the fair value of the derivative liabilities. We recorded contingent consideration from the 2016 acquisition of Ciclofilin, which is required to be carried at fair value. See Note 6 for additional information on the fair value of the contingent consideration.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Derivative Financial Instruments

We have issued common stock warrants in connection with the execution of certain equity financings. The fair value of the warrants, which were deemed to be derivative instruments based on certain contingent put features, was recorded as a derivative liability under the provisions of ASC Topic 815 Derivatives and Hedging (“ASC 815”) upon issuance. Subsequently, the liability is adjusted to fair value as of the end of each reporting period and the changes in the fair value of derivative liabilities are recorded in the statements of operations under the caption “Change in fair value of derivative financial instruments—warrants.” See Note 5 for additional information.

The fair value of the warrants, issued in connection with the October 2015, April 2016, and April 2018 common stock offerings were deemed to be derivative instruments due to certain contingent put feature, was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.

The warrants, issued in connection with the July 2018 Rights Offering (See Note 5) are deemed to be derivative instruments since if we do not maintain an effective registration statement, we are obligated to deliver registered shares upon exercise and settlement of the warrant because there are further registration and prospectus delivery requirements that are outside our control. Therefore, the fair value of the warrants was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.

The fair value of warrants was affected by changes in inputs to the Black-Scholes option pricing model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. This model uses Level 3 inputs, including stock price volatility, in the fair value hierarchy established by ASC 820 Fair Value Measurement. At March 31, 2020 and December 31, 2019, the fair value of all warrants was $15,303 and $5,623, respectively, which are classified as a long-term derivative liability on our condensed consolidated balance sheets.

Property, equipment and depreciation

As of March 31, 2020 and December 31, 2019, we had $48,445 and $57,166, respectively, of property and equipment, consisting primarily of computer equipment, furniture and fixtures. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful lives of the related assets. The estimated useful lives of the depreciable assets are 3 to 5 years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives, or the remaining term of the lease, whichever is shorter. Depreciation expense for the the three months ended March 31, 2020 and 2019 was $6,527 and $4,641 respectively. Expenditures for repairs and maintenance are charged to operations as incurred. We will periodically evaluate whether current events or circumstances indicate that the carrying value of our depreciable assets may not be recoverable. There were no adjustments to the carrying value of property and equipment at March 31, 2020 or December 31, 2019.

Goodwill and In-Process Research & Development

In accordance with ASC Topic 350, Intangibles — Goodwill and Other (“ASC Topic 350”), goodwill and acquired IPR&D are determined to have indefinite lives and, therefore, are not amortized. Instead, they are tested for impairment annually, in our fourth quarter, and between annual tests if we become aware of an event or a change in circumstances that would indicate the carrying value may be impaired.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable.

The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. We adopted ASU 2017-04 on January 1, 2020, and the adoption of this standard did not have a material effect on our condensed condolidated financial statements.

Goodwill relates to amounts that arose in connection with the acquisition of Ciclofilin. Goodwill represents the excess of the purchase price over the fair value of the net assets acquired when accounted for using the acquisition method of accounting for business combinations. As a result of the COVID-19 pandemic, we performed a qualitative assessment of goodwill and determined that it was not more likely than not that the fair value of our reporting was less than its carrying value. There was no impairment of goodwill for the three months ended March 31, 2020 and 2019.

IPR&D acquired in a business combination is capitalized as indefinite-lived assets on our condensed consolidated balance sheets at the acquisition-date fair value. Once the project is completed, the carrying value of the IPR&D is reclassified to other intangible assets, net and is amortized over the estimated useful life of the asset. Post-acquisition research and development expenses related to the IPR&D projects are expensed as incurred. The projected discounted cash flow models used to estimate the fair values of our IPR&D assets, acquired in connection with the Ciclofilin acquisition, reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including: (i) probability of successfully completing clinical trials and obtaining regulatory approval; (ii) market size, market growth projections, and market share; (iii) estimates regarding the timing of and the expected costs to advance clinical programs to commercialization; (iv) estimates of future cash flows from potential product sales; and (v) a discount rate. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The use of different inputs and assumptions could increase or decrease our estimated discounted future cash flows, the resulting estimated fair values and the amounts of related impairments, if any.

If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to the revised fair value with the related impairment charge recognized in the period in which the impairment occurs. If the carrying value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs.

As a result of the COVID-19 pandemic, we performed a qualitative assessment of IPR&D and determined that it was not more likely than not that the asset was impaired. There was no impairment of IPR&D for the three months ended March 31, 2020 and 2019.

Income Taxes

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We reduce the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that we will not realize some or all of the deferred tax asset. We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more-likely-than-not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.

In April 2019, we transferred state net operating loss tax credits and received approximately $1.0 million in connection with the sale of the state net operating losses to a third party recorded as an income tax benefit in the consolidated statement of operations. We received approval for the sale of net operating losses through participation in the New Jersey Technology Business Tax Certificate Transfer (NOL) Program.

Contingencies

In the normal course of business, we are subject to loss contingencies, such as legal proceedings and claims arising out of our business that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters. In accordance with ASC Topic 450, Accounting for Contingencies, (“ASC 450”), we record accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. In accordance with this guidance, we do not recognize gain contingencies until realized.

Research and Development

Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, license costs, regulatory and scientific consulting fees, as well as contract research, insurance and FDA consultants, are accounted for in accordance with ASC Topic 730, Research and Development, (“ASC 730”). Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.

We do not currently have any commercial biopharmaceutical products and does not expect to have such for several years, if at all. Accordingly, our research and development costs are expensed as incurred. While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that we have no history of successful commercialization of product candidates to base any estimate of the number of future periods that would be benefited.

Also as prescribed by ASC 730, non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts would be recognized as an expense. At March 31, 2020 and December 31, 2019, we had prepaid research and development costs of $1.1 million and $0.4 million, respectively.

Share-based payments

ASC Topic 718 “Compensation—Stock Compensation” (“ASC 718”) requires companies to measure the cost of employee and non-employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award. Generally, we issue stock options with only service-based vesting conditions and record the expense for awards using the straight-line method.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. We have a limited trading history in our common stock and lacks company-specific historical and implied volatility information. Therefore, the estimated expected stock volatility is based on the historical volatility of a publicly traded set of peer companies until such time as we have adequate historical data regarding the volatility of our own traded stock price. The expected term of stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future.

Foreign Exchange

The functional currency of Hepion Pharmaceuticals, Inc. and ContraVir Research Inc. is the U.S. dollar. The functional currency of Hepion Research Corp. is the Canadian dollar. Our reporting currency is the U.S. dollar. The assets and liabilities of Ciclofilin are translated into U.S. dollars using period-end exchange rates; income and expenses are translated using the average exchange rates for the reporting period. Unrealized foreign currency translation adjustments are deferred in accumulated other comprehensive loss, a separate component of shareholders’ equity. The amount of currency translation adjustment was immaterial at March 31, 2020 and December 31, 2019.

Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in other foreign exchange (gain) loss within the consolidated statements of operations. The impact of foreign exchange gains (losses) was immaterial at March 31, 2020 and December 31, 2019.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker views our operations and manages the business in one segment.

Net loss per share

Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC 260”) for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period.

4. Recent Accounting Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes. This guidance will be effective for us in the first quarter of 2021 on a prospective basis, and early adoption is permitted. We are currently evaluating the impact of the new guidance on our condensed consolidated financial statements.

In August of 2018, the FASB issued ASU 2018-13 — Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends disclosure requirements on fair value measurements in Topic 820. This amendment modifies the valuation process of fair

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

value measurements by removing the disclosure requirements for the valuation processes for Level 3 fair value measurements, clarifying the timing of the measurement uncertainty disclosure, and including the changes in unrealized gains and losses for recurring Level 3 fair value measurements in other comprehensive income if held at the end of the reporting period. It also allows the disclosure of other quantitative information in lieu of the weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019 and should be applied prospectively for the most recent period presented in the initial fiscal year of adoption. We adopted this standard on January 1, 2020 and the impact that this guidance had on our condensed consolidated financial statements was immaterial.

5. Stockholders’ Equity and Derivative Liability — Warrants

Series A Convertible Preferred Stock

During the period from August 5, 2016 to September 30, 2018, certain holders of our Series A Convertible Preferred Stock elected to convert approximately 1.2 million shares of Series A Convertible Preferred Stock into approximately 3.0 million shares of our common stock. For 2019 and the three months ended March 31, 2020, no shares of our Series A Convertible Preferred Stock were converted.

Series C Convertible Preferred Stock Issuance

On July 3, 2018, we completed a rights offering pursuant to our effective registration statement on Form S-1. We offered for sale units in the rights offering and each unit sold in connection with the rights offering consists of 1 share of our Series C Convertible Preferred Stock, or Series C, and common stock warrants (the “Rights Offering”). Upon completion of the offering, pursuant to the rights offering, we sold an aggregate of 10,826 units at an offering price of $1,000 per unit comprised of 10,826 shares of Series C and 88,928 common stock warrants. We received net proceeds of $9.9 million, after deducting expenses relating to the Rights Offering, including dealer-manager fees and offering expenses, totaling approximately $0.9 million, and excluding any proceeds received upon exercise of any warrants.

The common stock warrants are exercisable at $108.50 per share and subject to adjustments upon the occurrence of certain dilutive events. The warrants expire on the fifth anniversary from their original issuance date. We may redeem the warrants for $0.70 per warrant if our common stock closes above $434.00 per share for ten consecutive trading days provided that we may not do so prior to the first anniversary of the closing of the unit offering. The warrants were sold under a written public offering. If a warrant is exercised during a period where a registration statement is not declared effective, we cannot assert that settlement in unregistered shares is permitted. As a result, the warrants are liability classified and carried at their estimated fair value at each reporting until they are exercised, terminated or otherwise settled.

We determined that the Series C should not be classified as temporary equity due to its lack of senior liquidation preferences and is not redeemable on a fixed or determinable date.

The rights and preferences of the Series C are as follows:

Dividends. Holders of Series C shares are entitled to dividends, if and when declared on shares of common stock, on an “as-converted” basis.

Voting. Subject to certain preferred stock class votes specified in the certificate of designation, the holders of Series C shares shall have no voting rights.

Liquidation. Upon any voluntary or involuntary liquidation, dissolution or winding-up of us, holder of Series C shares shall be entitled to receive the same consideration as the holders of our common stock on an “as converted” basis.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Conversion. Each share of Series C is convertible into common stock at any time at the option of the holder thereof at the conversion price then in effect. The conversion price for the Series C is determined by dividing the stated value of $1,000 per share by $108.50 per share (subject to adjustments upon the occurrence of certain dilutive events).

At any time after the first anniversary of the original issuance date, we may, subject to certain conditions, require the conversion of Series C shares.

The gross proceeds of the offering were first allocated to the warrants based on the fair value of the warrants at that time, with the residual proceeds allocated to the Series C. All offering costs were allocated between the Series C and the warrants. In addition, the placement agent received, as compensation for the transaction, unregistered equity warrants to purchase 3,991 shares of our common stock priced at $119.70 per share. The fair value of the placement agent equity classified warrants was $0.2 million at the time of issuance and $0.1 million was allocated to the Series C and $0.1 million was allocated to the liability classified common stock warrants. All costs allocated to the liability classified warrants were expensed immediately and as a component of general and administrative expenses within our condensed consolidated statement of operations.

In connection with the issuance of the Series C and liability classified warrants, we recognized the intrinsic value of a beneficial conversion feature of $3.8 million. The beneficial conversion amount was computed as the difference between the Series C effective conversion price and the fair value of our common stock multiplied by that number of shares issuable upon conversion.

As a result of our issuance of convertible preferred shares that included a beneficial conversion feature, we may, upon conversion of the Series C, recognize any unamortized discount resulting from the initial allocation of proceeds issued to the liability classified warrants. During the year ended December 31, 2019, the holders of Series C shares converted 147 shares of Series C into 1,353 shares of common stock. As a result of the conversion, we recognized a preferred stock discount amortization to additional paid in capital of $77,721 as deemed dividends. During the year ended December 31, 2018, the holders of Series C shares converted 8,852 shares of Series C into 81,585 shares of common stock. As a result of the conversion, we recognized a deemed dividend charged to additional paid in capital of $4.7 million associated with the difference between the stated and carrying per share values of the Series C, including a $0.5 million accretion related to issuance costs that had been allocated to the Series C, which have been presented as a component of net loss attributable to common stockholders in our consolidated statement of operations. During the three months ended March 31, 2020, no shares of Series C were converted into common stock.

Beneficial Conversion Feature- Series C Convertible Preferred Stock

Each share of Series C is convertible into shares of common stock, at any time at the option of the holder at a conversion price of $108.50 per share. Based on the guidance in ASC 470-20-20, we determined that a beneficial conversion feature exists, as the effective conversion price for the Series C preferred shares at issuance was less than the fair value of the common stock into which the preferred shares are convertible. A beneficial conversion feature based on the intrinsic value of the date of issuances for the Series C was $3.8 million and the preferred stock was discounted by this amount. The beneficial conversion amount of $3.8 million was then accreted back to the preferred stock as a dividend charged to additional paid in capital as the preferred stock was 100% convertible immediately. The $3.8 million accretion was recorded as a dividend reflected in additional paid in capital and presented as a component of net loss attributable to common stockholders in our consolidated statement of operations for the year ended December 31, 2018.

Common Stock and Warrant Offering

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

were issued separately on October 13, 2015. The warrants are immediately exercisable and will be exercisable for a period of five years from the date of issuance at an exercise price of $2,380.00 per share. There is not, nor is there expected to be, any trading market for the warrants issued in the offering contemplated by the Underwriting Agreement.

The gross proceeds to us were $15.0 million, before deducting the underwriting discount and other offering expenses payable by us of approximately $1.5 million. If the warrants were exercised in full, we would receive additional proceeds of approximately $12.8 million.

If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statements of operations. Upon the issuance of these warrants, the fair value of approximately $4.4 million was recorded as derivative financial instruments liability-warrants.

The fair value of these liability classified warrants was estimated using the Black-Scholes option pricing model. We developed our own assumptions for use in the Black-Scholes option pricing model that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of our common stock, our stock price volatility (stock price volatility of comparable companies prior to 2020), the contractual term of the warrants, risk free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement. The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of March 31, 2020 and December 31, 2019:


	March 31,			December 31,
	2020			2019
Price of Hepion common stock	$	1.77		$	5.36
Expected warrant term (years)		0.53	years		0.78	years
Risk-free interest rate		0.33	%		1.66	%
Expected volatility		144	%		72	%
Dividend yield		—			—

On April 4, 2016, we closed a public offering of 8,803 shares of our common stock and warrants to purchase up to 4,401 shares of common stock, at a fixed combined price to the public of $795.20 under our prior shelf registration statement on Form S-3. The warrants are immediately exercisable and will be exercisable for a period of five years from the date of issuance at an exercise price of $952.00 per share. The gross proceeds to us were $7.0 million, before deducting the underwriting discount and other offering expenses payable by us of approximately $0.7 million. If the warrants were exercised in full, we would receive additional proceeds of approximately $4.2 million.

If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the Fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such Fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statement of

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

operations. Upon the issuance of these warrants, the fair value of approximately $1.5 million was recorded as derivative financial instruments liability-warrants.


	March 31,			December 31,
	2020			2019
Price of Hepion common stock	$	1.77		$	5.36
Expected warrant term (years)		1.01	years		1.26	years
Risk-free interest rate		0.33	%		1.66	%
Expected volatility		130	%		75	%
Dividend yield		—			—

On April 25, 2017, we closed a public offering of 21,429 shares of our common stock and warrants to purchase up to 10,714 shares of common stock, at a fixed combined price to the public of $560.00 under our prior shelf registration statement on Form S-3. The warrants are immediately exercisable and will be exercisable for a period of five years from the date of issuance at an exercise price of $700.00 per share. The gross proceeds to us were $12.0 million, before deducting the underwriting discount and other offering expenses payable by us of approximately $0.5 million. If the warrants were exercised in full, we would receive additional proceeds of approximately $7.5 million.

If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statement of operations and comprehensive loss. Upon the issuance of these warrants, the fair value of approximately $4.0 million was recorded as derivative financial instruments liability-warrants.

The fair value of these liability classified warrants were estimated using the Black-Scholes option pricing model. We developed our own assumptions for use in the Black-Scholes option pricing model that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of our common stock, our stock price volatility (stock price volatility of comparable companies prior to 2020), the contractual term of the warrants, risk free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of March 31, 2020 and December 31, 2019:


	March 31,			December 31,
	2020			2019
Price of Hepion common stock	$	1.77		$	5.36
Expected warrant term (years)		2.06	years		2.31	years
Risk-free interest rate		0.33	%		1.66	%
Expected volatility		117	%		69	%
Dividend yield		—			—

The warrants, issued in connection with the July 2018 Rights Offering are deemed to be derivative instruments since if we do not maintain an effective registration statement, we are obligated to deliver registered shares upon exercise and settlement of the warrant because there are further registration and prospectus delivery requirements that are outside of our control. Therefore, the fair value of the warrants was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.

The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of March 31, 2020 and December 31, 2019:


	March 31,			December 31,
	2020			2019
Price of Hepion common stock	$	1.77		$	5.36
Expected warrant term (years)		3.25	years		3.50	years
Risk-free interest rate		0.33	%		1.66	%
Expected volatility		116	%		65	%
Dividend yield		—			—

The following table sets forth the components of changes in our derivative financial instruments liability balance for the three months ended March 31, 2020:


		Number of		Derivative
		Warrants		Instrument
Date	Description	Outstanding		Liability
December 31, 2019	Balance of derivative financial instruments liability		107,998		5,623
	Change in fair value of warrants for the three months ended March 31, 2020		—		9,680
March 31, 2020	Balance of derivative financial instruments liability		107,998	$	15,303

Common Stock Offering

On February 12, 2020, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR, Inc., as agent (“B. Riley FBR”), pursuant to which we may offer and sell, from time to time, through B. Riley FBR, shares of our common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $7,000,000 (the “Shares”).

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The offer and sale of the Shares will be made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-229534) filed by us with the Securities and Exchange Commission (the “SEC”) on February 6, 2019, as amended on February 13, 2019, and declared effective by the SEC on February 19, 2019, as supplemented by a prospectus supplement dated February 12, 2020 and filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”).

Pursuant to the Sales Agreement, B. Riley FBR may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act, including sales made by means of ordinary brokers’ transactions, including on The Nasdaq Capital Market, at market prices or as otherwise agreed with B. Riley FBR. B. Riley FBR will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the Shares from time to time, based upon instructions from us, including any price or size limits or other customary parameters or conditions we may impose.

As of March 31, 2020, we sold 2,311,867 shares of our common stock resulting in net proceeds of $6.8 million under the Sales Agreement.

On March 27, 2020, we filed a prospectus supplement to the Form S-3 (File No. 333-229534) pursuant to which we may offer and sell an additional $4.6 million. As of April 30, 2020, we sold an additional 2,950,939 shares of our common stock resulting in net proceeds of $4.5 million under the Sales Agreement. As of April 30, 2020, we sold a total of 5,262,806 shares and received total proceeds of $11.3 million from the “at the market offerings”.

6. Fair Value Measurements

The following table presents our liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy at March 31, 2020 and December 31, 2019.


			Quoted Prices in		Significant
			Active Markets for		Other		Significant
			Identical Assets		Observable		Unobservable
			and Liabilities		Inputs		Inputs
Description	Fair value		(Level 1)		(Level 2)		(Level 3)
As of March 31, 2020:
Contingent consideration	$	2,460,000	$	—	$	—	$	2,460,000
Derivative liabilities related to warrants	$	15,303	$	—	$	—	$	15,303

As of December 31, 2019:
Contingent consideration	$	2,430,000	$	—	$	—	$	2,430,000
Derivative liabilities related to warrants	$	5,623	$	—	$	—	$	5,623

The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities- warrants in our condensed consolidated statement of operations. See Note 5 for a rollfoward of the derivative liability for the three months ended March 31, 2020. The financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we review the assets and liabilities that are subject to ASC 815-40. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

related milestone payment of $1,000,000 and issued 1,439 shares of our common stock with a fair value of $55,398, representing 2.5% of our issued and outstanding common stock as of June, 2016, to the Ciclofilin shareholders. As of March 31, 2020, due to the uncertainty in the timing of the clinical development of the associated product candidate, the entire balance is classified as a non-current liability. The following table presents the change in fair value of the contingent consideration for the three months ended March 31, 2020.


	Acquisition-
	related
	Contingent
	Consideration
Liabilities:
Balance at December 31, 2019	$	2,430,000
Change in fair value recorded in earnings		30,000
Balance at March 31, 2020	$	2,460,000

7. Indefinite-lived Intangible Assets and Goodwill

IPR&D

Our IPR&D asset consisted of the following at:


	Indefinite-lived
	Intangible Asset
CRV431 balance at December 31, 2019	$	3,190,000
Change in fair value during the three months ended March 31, 2020		—
CRV431 balance at March 31, 2020	$	3,190,000

No impairment losses were recorded on IPR&D during the three months ended March 31, 2020 and 2019.

Goodwill

The table below provides a roll-forward of our goodwill balance:


	Amount
Goodwill balance at December 31, 2019	$	1,870,924
Changes during the three months ended March 31, 2020		—
Goodwill balance at March 31, 2020	$	1,870,924

8. Accrued Liabilities

Accrued expenses consist of the following:


	March 31,		December 31,
	2020		2019
Payroll and related costs	$	190,596	$	346,244
Research and development		62,781		12,075
Legal fees		1,500		2,354
Accrued taxes		74,357		74,357
Other		83,608		58,606
Total accrued expenses	$	412,842	$	493,636

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

9. Accounting for Share-Based Payments

On June 3, 2013, we adopted the 2013 Equity Incentive Plan (the “Plan”). Stock options granted under the Plan typically will vest after three years of continuous service from the grant date and will have a contractual term of ten years. Stockholder and Board approval was obtained on December 2, 2014 to increase the number of authorized shares to 11,607 and on December 14, 2016 Stockholder and Board approval was obtained to increase the number of authorized shares to 13,750. Stockholder and Board approval was obtained on February 21, 2018 to increase the number of authorized shares to 40,535. As of March 31, 2020, we had 0 shares of common stock available for grant under the Plan.

We classify stock-based compensation expense in our condensed consolidated statement of operations in the same way the award recipient's payroll costs are classified or in which the award recipients' service payments are classified. We recorded stock-based compensation expense as follows:


	Three Months Ended
	March 31,
	2020		2019
General and administrative	$	5,910	$	10,365
Research and development		2,336		7,141
Total stock-based compensation expense	$	8,246	$	17,506

A summary of stock option activity and of changes in stock options outstanding under the Plan is presented below:


							Weighted				Weighted
							Average				Average
	Number of	Exercise Price					Exercise Price		Intrinsic		Remaining
	Options	Per Share					Per Share		Value		Contractual Term
Balance outstanding, December 31, 2019	41,271	$	3.24	-	$	2,452.80	$	194.83	$	43,182	8.42	years
Granted	—		—	-	$	—	$	—	$	—
Forfeited	—		—		$	—	$	—		—
Cancelled	—	$	—	-	$	—	$	—		—
Balance outstanding, March 31, 2020	41,271	$	3.24	-	$	2,452.80	$	209.07	$	—	8.33	years
Vested awards and those expected to vest at March 31, 2020	39,913	$	3.24	-	$	2,452.80	$	216.06	$	—	8.30	years
Vested and exercisable at March 31, 2020	14,415	$	3.24	-	$	2,452.80	$	586.07	$	—	6.52	years

There were no options granted to employees during the three months ended March 31, 2020 and 2019, respectively. The total fair value of the shares vested during the three months ended March 31, 2020 was de minimis.

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of our common stock for those stock options that had exercise prices lower than the fair value of our common stock.

As of March 31, 2020, the unrecognized compensation cost related to non-vested stock options outstanding, net of expected forfeitures, was approximately $0.1 million to be recognized over a weighted-average remaining vesting period of approximately 2.7 years.

The following weighted-average assumptions are used in the Black-Scholes valuation model to estimate fair value of stock option awards when granted to employees.

Risk-free interest rate—Based on the daily yield curve rates for U.S. Treasury obligations with maturities which correspond to the expected term of our stock options.

Dividend yield— We have not paid any dividends on our common stock since inception and do not anticipate paying dividends on our common stock in the foreseeable future.

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Expected volatility—Because we have a limited trading history in our common stock, we base expected volatility on that of comparable public development stage biotechnology companies.

Expected term—The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method provided in SAB No. 107, which SAB No. 107, options are considered to be “plain vanilla” if they have the following basic characteristics: (i) granted “at-the-money”; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable.

In December 2007, the SEC issued SAB No. 110, Share-Based Payment, (“SAB No. 110”). SAB No. 110 was effective January 1, 2008 and expresses the views of the Staff of the SEC with respect to extending the use of the simplified method, as discussed in SAB No. 107, in developing an estimate of the expected term of “plain vanilla” share options in accordance with ASC 718. We will use the simplified method until we have the historical data necessary to provide a reasonable estimate of expected life in accordance with SAB No. 107, as amended by SAB No. 110. For the expected term, we have “plain-vanilla” stock options, and therefore used a simple average of the vesting period and the contractual term for options granted as permitted by SAB No. 107.

Forfeitures—ASC 718 allows for the election of forfeitures to be estimated at the time of grant and revised if necessary, in subsequent periods if actual forfeitures differ from those estimates. At April 1, 2016, we determined that we had sufficient history of issuing stock options and decreased our estimated forfeiture rate from 10%, which was based on the historical experience of our former parent, to 3%, which is our actual historical forfeiture rate. The forfeiture rate was 10% through the end of the 3rd fiscal quarter ended March 31, 2016 and was the adjusted to 3% through the end of the fiscal year June 30, 2016 based on the aforementioned historical analysis. The forfeiture rate was 3% for the three months ended March 31, 2020 and 2019. We will continue to analyze the forfeiture rate on at least an annual basis or when there are any identified triggers that would justify immediate review.

10. Loss per Share

Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC 260”) for all periods presented. In accordance with ASC 260, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. In addition, the net loss attributable to common stockholders’ is adjusted for the preferred stock deemed dividends related accretion of beneficial conversion feature and other discount on this instrument for the periods in which the preferred stock is outstanding.

The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:



	Three Months Ended
	March 31,
Basic and diluted net (loss) income per common share	2020		2019
Numerator:
Net loss	$	(4,226,617)	$	(1,983,711)
Preferred stock deemed dividend		—		(24,321)
Net loss attributable to common stockholders	$	(4,226,617)	$	(2,008,032)
Denominator:
Weighted average common shares outstanding		4,345,699		250,126
Net loss per share of common stock—basic and diluted	$	(0.97)	$	(8.03)

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The following outstanding securities at March 31, 2020 and 2019 have been excluded from the computation of basic and diluted weighted shares outstanding, as they would have been anti-dilutive:



	Three Months Ended
	March 31,
	2020	2019
Common shares issuable upon conversion of Series A preferred stock	3,184	3,184
Common shares issuable upon conversion of Series C preferred stock	16,839	17,770
Stock options	41,271	9,013
Warrants – liability classified	107,998	107,998
Warrants – equity classified	2,428,568	3,991
Total	2,597,860	141,956

The liability and equity classified warrants disclosed above have been excluded from the computation of basic and diluted earnings per share because the exercise price of the warrants exceeds the average market price of our common stock for the period they were outstanding.

11. Commitments and Contingencies

Contractual Obligations

In August 2014, we entered into a lease for corporate office space in Edison, New Jersey. In December 2017, we entered an amendment to the lease for corporate office space in Edison, New Jersey expanding the office footprint and extending the lease for an approximate 5-year period. In May 2018, we entered into a 3 year lease for office equipment to be used at our corporate office space in Edison, New Jersey. In October 2019, we entered into a 3 year lease for office and research laboratory space in Edmonton, Canada. Prior to signing this lease, the space was previously on a month to month basis.

Legal Proceedings

We are involved in legal proceedings of various types. Significant judgment is required to determine both the likelihood and the estimated amount of a loss related to such matters. Additionally, while any litigation contains an element of uncertainty, we have at this time no reason to believe that the outcome of such proceedings or claims will have a material adverse effect on our condensed consolidated financial condition or results of operations.

Leases

We account for leases in accordance with ASC Topic 842, Leases, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) the customer has the right to control the use of the identified asset.

Operating leases where we are the lessee are included under the caption “Right of Use Assets” on our condensed consolidated balance sheets. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. Key estimates and judgments include how we determine (1) the discount rate used to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments.

The Right-Of-Use (“ROU”) asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease

Table of Contents

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

We adopted ASC 842 in the first quarter of 2019 using an alternative modified retrospective approach, in which prior periods will not be restated. As a result of the adoption, as of January 1, 2019, we recognized an operating lease liability of $0.8 million based on the present value of the minimum rental payments of the leases and a corresponding ROU asset of $0.8 million. As of March 31, 2020, the ROU assets are $0.7 million, the current lease liabilities are $0.3 million, and the non-current lease liabilities are $0.5 million. The discount rate used to account for our operating leases under ASC 842 is our estimated incremental borrowing rate of 6.5%.

Rent expense for the three months ended March 31, 2020 and 2019 was $0.1 and $0.1, respectively. The weighted average remaining term of our noncancelable operating leases is 2.88 years. Future minimum rental payments under our noncancelable operating leases at March 31, 2020 is as follows:


2020	$	210,255
2021		282,176
2022		267,425
2023		53,902
2024 and thereafter		—
Total		813,758
Present value adjustment		(68,283)
Lease liability at March 31, 2020	$	745,475

Employment Agreements

We have employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control, termination without cause or retirement, occur.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our condensed consolidated financial statements and other financial information appearing elsewhere in this quarterly report. In addition to historical information, the following discussion and other parts of this quarterly report contain forward-looking statements. You can identify these statements by forward-looking words such as “plan,” “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. Forward-looking statements include information concerning possible or assumed future business success or financial results. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Accordingly, we do not undertake any obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties set forth under “Risk Factors” in our Annual Report on Form 10-K as of and for the year ended December 31, 2019 filed with the United States Securities and Exchange Commission (“SEC”). Accordingly, to the extent that this Report contains forward-looking statements regarding the financial condition, operating results, business prospects or any other aspect of us, please be advised that our actual financial condition, operating results and business performance may differ materially from that projected or estimated by us in forward-looking statements, and you should not unduly rely on such statements.

Impact of COVID-19

The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation and its impact on our financial condition, liquidity, operations, suppliers, industry, and workforce.

Table of Contents

Business Overview

We are a biopharmaceutical company headquartered in Edison, New Jersey, focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (“HCC”) associated with non-alcoholic steatohepatitis (“NASH”), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 is a cyclophilin inhibitor that targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. CRV431 additionally shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease.

NASH is the form of liver disease that is triggered by what has come to be known as the “Western diet”, characterized especially by high-fat, high-sugar, and processed foods. Among the effects of a prolonged Western diet is fat accumulation in liver cells (steatosis) which is described as non-alcoholic fatty liver disease (“NAFLD”) and can predispose cells to injury. NAFLD may evolve into NASH when the fatty liver begins to progress through stages of cell injury, inflammation, fibrosis, and carcinogenesis. People who develop NASH often have additional predisposing conditions such as diabetes and hypertension, but the exact biochemical events that trigger and maintain the progression are not well known. Many people in the early stages of disease do not have significant symptoms and therefore do not know that they have it. NASH becomes evident and a major concern when the liver becomes fibrotic and puts the individual at increased risk of developing cirrhosis and other complications. Individuals with advanced liver fibrosis have significantly higher risk of developing liver cancer, although cancer may also arise in some patients before significant hepatitis or fibrosis. NASH is increasing worldwide at an alarming rate due to the spread of the Western diet, obesity, and other related conditions. Approximately 4-5% of the global population is estimated to have NASH, and that proportion is higher in the USA. Considering the serious outcomes linked to advancing NASH, the economic and social burden of the disease is enormous. There are no simple blood tests to diagnose or track the progression of NASH, and no drugs are approved to specifically treat the disease.

FINANCIAL OPERATIONS OVERVIEW

From inception through March 31, 2020, we have an accumulated deficit of $87.4 million and we have not generated any revenue from operations and expect to incur additional losses to perform further research and development activities and do not currently have any commercial biopharmaceutical products. We do not expect to have such for several years, if at all.

Table of Contents

On May 28, 2019, we effected a 1 for 70 reverse stock split of our common stock. The par value and the number of authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented have been adjusted retroactively to reflect the reverse stock split.

Pursuant to the Sales Agreement, B. Riley FBR may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act, including sales made by means of ordinary brokers’ transactions, including on The Nasdaq Capital Market, at market prices or as otherwise agreed with B. Riley FBR. B. Riley FBR will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the Shares from time to time, based upon instructions from the Company, including any price or size limits or other customary parameters or conditions the Company may impose.

As of March 31, 2020, we sold 2,311,867 shares of our common stock resulting in net proceeds of $6.8 million under the Sales Agreement.

Our product development efforts are in their early stages and we cannot make estimates of the costs or the time they will take to complete. The risk of completion of any program is high because of the many uncertainties involved in bringing new drugs to market including the long duration of clinical testing, the specific performance of proposed products under stringent clinical trial protocols, the extended regulatory approval and review cycles, our ability to raise additional capital, the nature and timing of research and development expenses and competing technologies being developed by organizations with significantly greater resources.

CRITICAL ACCOUNTING POLICIES

Our condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, costs and expenses, income taxes and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.

During the three months ended March 31, 2020, there were no significant changes to our critical accounting policies and estimates as described in the financial statements contained in the Annual Report on Form 10-K for the year ended December 31, 2019.

OFF-BALANCE SHEET ARRANGEMENTS

We had no off-balance sheet arrangements as of March 31, 2020.

Table of Contents

RECENT ACCOUNTING PRONOUNCEMENTS

Please refer to Note 4 of Notes to Condensed Consolidated Financial Statements, Recent Accounting Pronouncements, in this Quarterly Report on Form 10-Q.

JOBS Act

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include:

●

requirement to provide only two years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;

●

reduced disclosure about our executive compensation arrangements;

●

no non-binding advisory votes on executive compensation or golden parachute arrangements; and

●

exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.

We have irrevocably elected not to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act, and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

We may take advantage of these provisions up to the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement or such earlier time that we are no longer an emerging growth company. We could remain an “emerging growth company” until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the first public sale of equity securities in October 2015, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeded $700.0 million as of the prior December 31st, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

To the extent that we continue to qualify as a “smaller reporting company,” as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company, including: (1) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (2) scaled executive compensation disclosures; and (3) the requirement to provide only two years of audited financial statements, instead of three years.

Table of Contents

RESULTS OF OPERATIONS

Comparison of the three months ended March 31, 2020 and 2019:


	Three Months Ended
	March 31,
	2020		2019		Change
Revenues	$	—	$	—	$	—
Costs and Expenses:
Research and development		2,637,331		518,040		2,119,291
General and administrative		1,549,606		1,403,660		145,946
Loss from operations		(4,186,937)		(1,921,700)		(2,265,237)

Other income (expense):
Change in fair value of debt		—		(59,641)		59,641
Interest expense		—		(98,287)		98,287
Change in fair value of derivative instruments – warrants and contingent consideration		(39,680)		95,917		(135,597)
Loss before income taxes		(4,226,617)		(1,983,711)		(2,242,906)
Income tax benefit		—		—		—
Net loss	$	(4,226,617)	$	(1,983,711)	$	(2,242,906)

We had no revenues during the three months ended March 31, 2020 and 2019, respectively, because we do not have any commercial biopharmaceutical products and we do not expect to have such products for several years, if at all.

Research and development expenses for the three months ended March 31, 2020 and 2019 amounted to $2.6 million and $0.5 million, respectively. The $2.1 million increase was primarily due to an increase of $0.7 million for costs related to drug supply and a $1.4 million increase attributable to the phase 1 and phase 2 studies related to CRV431.

General and administrative expenses for the three months ended March 31, 2020 and 2019 amounted to $1.5 million and $1.4 million, respectively. The increase of $0.1 million is primarily related to an increase in insurance costs.

Net loss for the three months ended March 31, 2020 was $4.2 million, which was the result of the operating expenses discussed above and a decrease of $39,680 for the change in fair value of derivative instruments related to our warrants and contingent consideration. Net loss for the three months ended March 31, 2019 was $2.0 million, which was the result of the operating expenses discussed above, a loss of $0.1 million for the change in fair value of debt, a $0.1 million loss for interest expense, which was offset by income of $0.1 million resulting from the change in fair value of derivative instruments related to our warrants and contingent consideration.

Liquidity and Capital Resources

As of March 31, 2020, we had working capital of $15.8 million compared to working capital of $13.1 million as of December 31, 2019. The increase of $2.7 million in working capital is primarily related to an increase in cash and cash equivalents of $2.1 million.

Cash Flows

The following table summarizes our cash flows for the three months ended March 31, 2020 and 2019:


	Three Months Ended
	March 31,
	2020		2019
Net cash provided by (used in):
Operating activities	$	(4,677,962)	$	(2,058,427)
Investing activities		2,194		(37,849)
Financing activities		6,800,465		946,453
Net increase (decrease) in cash	$	2,124,697	$	(1,149,823)

Table of Contents

As of March 31, 2020, we had $16.0 million in cash. Net cash used in operating activities was $4.7 million for the three months ended March 31, 2020 consisting of our net loss of $4.2 million. Changes in working capital accounts had a negative impact of $0.2 million on cash.

Net cash used in operating activities was $2.1 million for the the three months ended March 31, 2019 consisting primarily of our net loss of $2.0 million. Changes in working capital accounts had a negative impact of $0.2 million on cash.

Net cash used in investing activities during the three months ended March 31, 2020 and 2019 was immaterial in both periods.

Net cash provided by financing activities was $6.8 million for the three months ended March 31, 2020 due primarily to the issuance of common stock, net of issuance costs.

Net cash provided by financing activities was $0.9 million for the the three months ended March 31, 2019 due primarily to the issuance of short term debt and common stock of $1.3 million, offset by the repayment of debt of $0.3 million.

On February 12, 2020, we entered into the Sales Agreement with B. Riley FBR, Inc., as agent pursuant to which we may offer and sell, from time to time, through B. Riley FBR, shares of our Common Stock having an aggregate offering price of up to $7,000,000.

Operating and Capital Expenditure Requirements

As of March 31, 2020, we had an accumulated deficit of $87.4 million and expect to incur a significant increase in operating losses for the next several years as we expand our research, development and clinical trials of CRV431. We are unable to predict the extent of any future losses or when we will become profitable, if at all.

The condensed consolidated financial statements as of March 31, 2020 have been prepared under the assumption that we will continue as a going concern within one year after the financial statements are issued. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We will be required to raise additional capital within the next year to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels. We cannot be certain that additional funding will be available on acceptable terms, or at all. Recently worldwide economic conditions and the international equity and credit markets have significantly deteriorated and may remain difficult for the foreseeable future. These developments will make it more difficult to obtain additional equity or credit financing, when needed. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct, delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.

Contractual Obligations and Commitments

Please refer to Note 11 of Notes to Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for a description of our contractual obligations and commitments.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures. Based on an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) required

Table of Contents

by paragraph (b) of Rule 13a-15 or Rule 15d-15, as of March 31, 2020, our Principal Executive Officer and Principal Financial Officer have concluded that, due to the material weaknesses in our internal control over financial reporting, our disclosure controls and procedures were not effective.

Changes in Internal Control over Financial Reporting

As required by Rule 13a-15(d) of the Exchange Act, our management, including our principal executive officer and our principal financial officer, conducted an evaluation of the internal control over financial reporting to determine whether any changes occurred during the quarter ended the three months ended March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. There have been no changes in our internal controls over financial reporting during three months ended March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We are committed to the remediation of the material weaknesses described in our Annual Report on Form 10-K, as well as the continued improvement of our internal control over financial reporting. We are in the process of taking steps to remediate the identified material weaknesses and continue to evaluate our internal controls over financial reporting, including the following:

●

We assessed our companywide accounting resource requirements and as a result have hired, and are in the process of hiring additional experienced accounting personnel, and taken steps to improve the overall efficiency of our accounting and reporting processes. We will continue to regularly monitor our accounting resource sufficiency, our internal controls processes and procedures, and we may undertake additional measures as deemed necessary to fully remediate the control deficiencies.

●

We are in the process of implementing several software solutions to improve our financial reporting process.

●

We are utilizing the services of external consultants for non-routine and\or technical accounting issues as they arise.

As we continue our evaluation and improve our internal control over financial reporting, management may identify and take additional measures to address control deficiencies. We cannot assure you that we will be successful in remediating the material weaknesses in a timely manner.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1A. RISK FACTORS

There have been no material changes to the Risk Factors we previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.

ITEM 6. EXHIBITS


31.1		Certification of Chief Executive Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.
31.2		Certification of Principal Financial Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.
32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema
101.CAL		XBRL Taxonomy Extension Calculation Linkbase
101.DEF		XBRL Taxonomy Extension Definition Linkbase
101.LAB		XBRL Taxonomy Label Linkbase
101.PRE		XBRL Taxonomy Extension Presentation Linkbase

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

20
	HEPION PHARMACEUTICALS, INC. (Registrant)

Date: 06/29/2020	By:	/s/ ROBERT FOSTER
		Robert Foster
		Chief Executive Officer
		(Principal Executive Officer)

Date: 06/29/2020	By:	/s/ JOHN CAVAN
		John Cavan
		Chief Financial Officer

EX-31.1 2 hepa-20200331ex311e1fe07.htm EX-31.1

EXHIBIT 31.1

CERTIFICATIONS

I, Robert Foster, certify that:

1)I have reviewed this report on Form 10-Q of Hepion Pharmaceuticals, Inc.

2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4)The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5)The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions);

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: June 29, 2020	/s/ Robert Foster
	Robert Foster
	Chief Executive Officer and Director (Principal Executive Officer)

EX-31.2 3 hepa-20200331ex312ee6556.htm EX-31.2

EXHIBIT 31.2

CERTIFICATIONS

I, John Cavan, certify that:

1)I have reviewed this report on Form 10-Q of Hepion Pharmaceuticals, Inc.

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: June 29, 2020	/s/ John Cavan
	John Cavan
	Chief Financial Officer

EX-32.1 4 hepa-20200331ex3219c435d.htm EX-32.1

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

HEPION PHARMACEUTICALS, INC.

FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2020

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I am the Chief Executive Officer of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”). I am delivering this certificate in connection with the Form 10-Q of the Company for the quarter ended March 31, 2020 and filed with the Securities and Exchange Commission (“Form 10-Q”).

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: June 29, 2020	/s/ Robert Foster
	Robert Foster
	Chief Executive Officer and Director (Principal Executive Officer)

EX-32.2 5 hepa-20200331ex3226a97d7.htm EX-32.2

EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

HEPION PHARMACEUTICALS, INC.

FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2020

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I am the Chief Financial Officer of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”). I am delivering this certificate in connection with the Form 10-Q of the Company for the quarter ended March 31, 2020 and filed with the Securities and Exchange Commission (“Form 10-Q”).


Date: June 29, 2020	/s/ John Cavan
	John Cavan
	Chief Financial Officer

GRAPHIC 6 hepa-20200331x10q002.jpg GRAPHIC begin 644 hepa-20200331x10q002.jpg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hepa-20200331.xml EX-101.INS 0001583771 hepa:October132015Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001583771 hepa:October132015Member us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001583771 hepa:October132015Member us-gaap:MeasurementInputExpectedTermMember 2020-03-31 0001583771 hepa:July3rd2018Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001583771 hepa:July3rd2018Member us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001583771 hepa:July3rd2018Member us-gaap:MeasurementInputExpectedTermMember 2020-03-31 0001583771 hepa:April42016Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001583771 hepa:April42016Member us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001583771 hepa:April42016Member us-gaap:MeasurementInputExpectedTermMember 2020-03-31 0001583771 hepa:April252017Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001583771 hepa:April252017Member us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001583771 hepa:April252017Member us-gaap:MeasurementInputExpectedTermMember 2020-03-31 0001583771 hepa:October132015Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001583771 hepa:October132015Member us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001583771 hepa:October132015Member us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001583771 hepa:July3rd2018Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001583771 hepa:July3rd2018Member us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001583771 hepa:July3rd2018Member us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001583771 hepa:April42016Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001583771 hepa:April42016Member us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001583771 hepa:April42016Member us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001583771 hepa:April252017Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001583771 hepa:April252017Member us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001583771 hepa:April252017Member us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001583771 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2019-01-01 2019-03-31 0001583771 us-gaap:PrivatePlacementMember 2019-01-01 2019-03-31 0001583771 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2019-01-01 2019-03-31 0001583771 2019-05-28 2019-05-28 0001583771 us-gaap:RetainedEarningsMember 2020-03-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001583771 us-gaap:RetainedEarningsMember 2019-12-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001583771 us-gaap:RetainedEarningsMember 2019-03-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001583771 us-gaap:RetainedEarningsMember 2018-12-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0001583771 us-gaap:CommonStockMember 2020-03-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-03-31 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-03-31 0001583771 us-gaap:CommonStockMember 2019-03-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001583771 hepa:October132015Member 2020-03-31 0001583771 hepa:July3rd2018Member 2020-03-31 0001583771 hepa:April42016Member 2020-03-31 0001583771 hepa:April252017Member 2020-03-31 0001583771 hepa:October132015Member 2019-12-31 0001583771 hepa:July3rd2018Member 2019-12-31 0001583771 hepa:April42016Member 2019-12-31 0001583771 hepa:April252017Member 2019-12-31 0001583771 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001583771 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001583771 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001583771 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001583771 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001583771 us-gaap:EmployeeStockOptionMember 2019-12-31 0001583771 us-gaap:StockCompensationPlanMember 2020-03-31 0001583771 us-gaap:StockCompensationPlanMember 2018-02-21 0001583771 us-gaap:StockCompensationPlanMember 2016-12-14 0001583771 us-gaap:StockCompensationPlanMember 2014-12-02 0001583771 us-gaap:StockCompensationPlanMember 2013-06-03 2013-06-03 0001583771 us-gaap:StockCompensationPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001583771 us-gaap:StockCompensationPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001583771 us-gaap:StockCompensationPlanMember 2020-01-01 2020-03-31 0001583771 us-gaap:StockCompensationPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001583771 us-gaap:StockCompensationPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001583771 us-gaap:StockCompensationPlanMember 2019-01-01 2019-03-31 0001583771 hepa:CiclofilinPharmaceuticalsInc.Member 2016-06-01 2016-06-30 0001583771 srt:MinimumMember 2020-01-01 2020-03-31 0001583771 srt:MaximumMember 2020-01-01 2020-03-31 0001583771 srt:ScenarioForecastMember hepa:AtMarketIssuanceSalesAgreementMember 2020-04-30 2020-04-30 0001583771 srt:ScenarioForecastMember 2020-04-30 2020-04-30 0001583771 hepa:AtMarketIssuanceSalesAgreementMember 2020-01-01 2020-03-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2018-07-03 0001583771 us-gaap:SeriesCPreferredStockMember 2020-03-31 0001583771 us-gaap:SeriesCPreferredStockMember 2019-12-31 0001583771 us-gaap:SeriesCPreferredStockMember 2018-07-03 0001583771 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001583771 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001583771 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001583771 hepa:OfficeAndResearchLaboratoryMember 2019-10-31 0001583771 us-gaap:OfficeEquipmentMember 2018-05-31 0001583771 hepa:OfficeSpaceMember 2017-12-31 0001583771 2019-04-01 2019-04-30 0001583771 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-03-31 0001583771 us-gaap:FairValueInputsLevel3Member hepa:ContingentConsiderationMember 2020-03-31 0001583771 us-gaap:FairValueInputsLevel3Member hepa:ContingentConsiderationMember 2019-12-31 0001583771 us-gaap:FairValueInputsLevel3Member hepa:ContingentConsiderationMember 2020-01-01 2020-03-31 0001583771 hepa:October132015Member 2020-01-01 2020-03-31 0001583771 hepa:July3rd2018Member 2020-01-01 2020-03-31 0001583771 hepa:April42016Member 2020-01-01 2020-03-31 0001583771 hepa:April252017Member 2020-01-01 2020-03-31 0001583771 us-gaap:EmployeeStockOptionMember 2020-03-31 0001583771 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001583771 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2020-03-31 0001583771 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001583771 hepa:April252017Member us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2017-04-25 0001583771 hepa:April42016Member us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2016-04-04 0001583771 hepa:October132015Member us-gaap:FairValueInputsLevel3Member 2015-10-13 0001583771 srt:ScenarioForecastMember hepa:PaycheckProtectionProgramLoanMember 2020-04-13 0001583771 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001583771 us-gaap:SeriesAPreferredStockMember 2020-03-31 0001583771 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001583771 us-gaap:CommonStockMember 2019-12-31 0001583771 us-gaap:CommonStockMember 2018-12-31 0001583771 us-gaap:SeriesAPreferredStockMember 2018-09-30 0001583771 us-gaap:SeriesCPreferredStockMember 2019-01-01 2019-12-31 0001583771 us-gaap:SeriesAPreferredStockMember 2016-08-05 2018-09-30 0001583771 hepa:AtMarketIssuanceSalesAgreementMember 2020-02-12 0001583771 us-gaap:WarrantMember 2020-03-31 0001583771 us-gaap:WarrantMember 2019-12-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:WarrantMember 2018-07-03 0001583771 hepa:April252017Member us-gaap:WarrantMember 2017-04-25 0001583771 hepa:April42016Member us-gaap:WarrantMember 2016-04-04 0001583771 hepa:October132015Member us-gaap:WarrantMember 2015-10-13 0001583771 2019-03-31 0001583771 2018-12-31 0001583771 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001583771 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001583771 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001583771 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001583771 us-gaap:MeasurementInputSharePriceMember 2016-06-10 0001583771 us-gaap:MeasurementInputDiscountRateMember 2016-06-10 0001583771 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001583771 us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-03-31 0001583771 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-03-31 0001583771 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001583771 hepa:WarrantsLiabilityMember 2020-01-01 2020-03-31 0001583771 us-gaap:WarrantMember 2019-01-01 2019-03-31 0001583771 us-gaap:SeriesCPreferredStockMember 2019-01-01 2019-03-31 0001583771 us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-03-31 0001583771 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001583771 hepa:WarrantsLiabilityMember 2019-01-01 2019-03-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:OverAllotmentOptionMember 2018-07-03 0001583771 us-gaap:WarrantMember 2018-07-03 2018-07-03 0001583771 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001583771 hepa:CiclofilinPharmaceuticalsInc.Member 2018-10-01 2018-10-31 0001583771 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001583771 2016-04-01 2016-04-01 0001583771 2016-04-01 2016-06-30 0001583771 2016-01-01 2016-03-31 0001583771 2015-07-01 2016-06-30 0001583771 us-gaap:SeriesCPreferredStockMember 2018-07-03 2018-07-03 0001583771 hepa:April42016Member 2016-04-04 2016-04-04 0001583771 hepa:October132015Member 2015-10-13 2015-10-13 0001583771 2020-03-31 0001583771 2019-12-31 0001583771 hepa:April252017Member 2017-04-25 2017-04-25 0001583771 hepa:April252017Member 2017-04-25 0001583771 hepa:April42016Member 2016-04-04 0001583771 hepa:October132015Member 2015-10-13 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:WarrantMember us-gaap:OverAllotmentOptionMember 2018-07-03 2018-07-03 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:OverAllotmentOptionMember 2018-07-03 2018-07-03 0001583771 us-gaap:OverAllotmentOptionMember 2018-07-03 2018-07-03 0001583771 2019-01-01 2019-12-31 0001583771 2018-01-01 2018-12-31 0001583771 hepa:AtMarketIssuanceSalesAgreementMember 2020-03-27 2020-03-27 0001583771 hepa:AtMarketIssuanceSalesAgreementMember 2020-02-12 2020-02-12 0001583771 hepa:April252017Member us-gaap:WarrantMember 2017-04-25 2017-04-25 0001583771 hepa:April42016Member us-gaap:WarrantMember 2016-04-04 2016-04-04 0001583771 hepa:October132015Member us-gaap:WarrantMember 2015-10-13 2015-10-13 0001583771 us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-03-31 0001583771 us-gaap:SeriesCPreferredStockMember 2018-01-01 2018-12-31 0001583771 2019-01-01 2019-03-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001583771 2020-06-19 0001583771 2020-01-01 2020-03-31 hepa:segment xbrli:pure hepa:item iso4217:USD xbrli:shares iso4217:USD xbrli:shares false --12-31 Q1 2020 2020-03-31 10-Q 0001583771 9025061 Yes true true Non-accelerated Filer Yes HEPION PHARMACEUTICALS, INC. false true -24321 24321 733374 <div> <div> 2. Basis of Presentation and Going Concern    These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet as of December 31, 2019 was derived from the audited annual consolidated financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2019 contained in our Annual Report on Form 10-K.   Principles of Consolidation   The accompanying condensed consolidated financial statements include our accounts and the accounts of our subsidiaries, Contravir Research Inc. and Hepion Research Corp, which conduct their operations in Canada. All intercompany balances and transactions have been eliminated in consolidation.   Reverse Stock Split   On May 28, 2019, we effected a 1 for 70 reverse stock split of our common stock. The par value and the number of authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these financial statements have been adjusted retroactively to reflect the reverse stock split.   Going Concern   As of March 31, 2020, we had $16.0 million in cash, we had an accumulated deficit of $87.4 million, and we had working capital of $15.8 million. For the three months ended March 31, 2020, cash used in operating activities was $4.7 million and we had a net loss of $4.2 million. We have not generated revenue to date and have incurred substantial losses and negative cash flows from operations since our inception. We have historically funded our operations through issuances of convertible debt, common stock and preferred stock. We expect to continue to incur losses for the next several years as we expand our research, development and clinical trials of CRV431. We are unable to predict the extent of any future losses or when we will become profitable, if at all.   These condensed consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.   We will be required to raise additional capital within the next year to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct business. If we are unable to raise additional capital when required or on acceptable terms, we may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.   COVID-19 Pandemic   On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.   The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation and its impact on our financial condition, liquidity, operations, suppliers, industry, and workforce.   We may experience delays in the conduct of clinical testing of our product candidate. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. The COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidate. The evolving COVID-19 pandemic is also likely to directly or indirectly impact the pace of enrollment in our CRV431 clinical trials for at least the next several months and possibly longer as patients may avoid or may not be able to travel to healthcare facilities and physicians' offices unless due to a health emergency. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a clinical trial, in securing clinical trial agreements with prospective sites with acceptable terms, in obtaining institutional review board approval to conduct a clinical trial at a prospective site, in recruiting patients to participate in a clinical trial, related to the COVID-19 pandemic, or in obtaining sufficient supplies of clinical trial materials. Any delays in completing our clinical trials will increase our costs, slow down our product development, timeliness and approval process and delay our ability to generate revenue.   The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change and we do not yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. Although we cannot estimate the length or gravity of the impact of the COVID-19 outbreak nor estimate the potential impact to our fiscal year 2020 financial statements at this time, if the pandemic continues, it could have a material adverse effect on our results of future operations, financial position, liquidity, and capital resources, and those of the third parties on which we rely in fiscal year 2020.   On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), as amended on June 5, 2020 by the Paycheck Protection Program (“PPP”). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. On April 13, 2020, we were granted a loan (the “Loan”) from JPMorgan Chase Bank, N.A. in the aggregate amount of $176,585, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act. We are continuing to evaluate and examine the impacts the CARES Act may have on our business, results of operations, financial condition or liquidity.    The Loan, which was in the form of a Note dated April 13, 2020 issued by us, matures on April 13, 2022 and bears interest at a rate of 0.98% per annum, payable monthly commencing on November 13, 2020. The Note may be prepaid by us at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, rent and utilities. We intend to use the entire Loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act.  We intend to comply with the loan forgiveness provisions in the legislation; however, there can be no assurance that we will obtain full forgiveness of the loans based on the legislation.   <div /></div> </div> 3800000 3800000 <div> <div> <a name="NotestoConsolidatedFinancialStatements_4"></a>1. Business Overview   Hepion Pharmaceuticals, Inc. (we, our, or us) is a biopharmaceutical company headquartered in Edison, New Jersey, focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (“HCC”) associated with non-alcoholic steatohepatitis (“NASH”), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 is a cyclophilin inhibitor that targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. CRV431 additionally shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease.   On July 18, 2019, we filed a certificate of amendment (the “Certificate of Amendment”) to our certificate of incorporation (the “Certificate”) to change our name from “ContraVir Pharmaceuticals, Inc.” to “Hepion Pharmaceuticals, Inc.” The name change became effective as of July 18, 2019.   We are developing CRV431 as our lead molecule. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. To date, in vitro and/or in vivo studies have demonstrated reductions in HBV DNA, HBsAg, HBeAg, inhibition of virus uptake (NTCP transport inhibition), and stimulation of innate immunity. Importantly, in vivo studies in a NASH model of fibrosis and HCC have repeatedly demonstrated CRV431 reduces fibrosis scores and overall liver tumor burden. Hence, CRV431 is a pleiotropic molecule that may not only treat liver disease but may also serve to reduce important risk factors (e.g., HBV) for developing the disease. We have completed a phase 1 study with CRV431 demonstrating safety, tolerability, and pharmacokinetics (PK).   CRV431   On May 10, 2018, we submitted an Investigational New Drug Application (“IND”) to the U.S. Food and Drug Administration (“FDA”) to support initiation of our CRV431 HBV clinical development program in the United States and received approval in June 2018. We completed the first segment of Phase 1 clinical activities for CRV431 in October 2018 wherein we reached a major clinical milestone of positive data from a Phase I trial of CRV431 in humans. This achievement triggered the first milestone payment, as stated in the Merger Agreement for the acquisition of Ciclofilin Pharmaceuticals, Inc. (“Ciclofilin”) and we paid a related milestone payment of $1,000,000 and issued 1,439 shares of our common stock with a fair value of $55,398, representing 2.5% of our issued and outstanding common stock as of June 2016, to the Ciclofilin shareholders.   On June 17, 2019, we submitted an IND to the FDA to support initiation of our CRV431 NASH clinical development program in the United States and received approval in July 2019. <div /></div> </div> 59641 P5Y P5Y P5Y 7000000 4600000 4700000 77721 -59641 95917 -39680 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Derivative </td> </tr> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Instrument </td> </tr> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Date </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Outstanding </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Liability </td> </tr> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> December 31, 2019 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance of derivative financial instruments liability </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 107,998 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,623 </td> </tr> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value of warrants for the three months ended March 31, 2020 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9,680 </td> </tr> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> March 31, 2020 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance of derivative financial instruments liability </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 107,998 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15,303 </td> </tr> </table></div>   <div /></div> </div> 200000 100000 100000 1680 795.20 560.00 P90D P90D P90D 2354 1500 23906 10 1.00 1250000 12800000 4200000 7500000 0.70 434.00 12075 62781 <div> <div> The following table presents the change in fair value of the contingent consideration for the three months ended March 31, 2020.   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Acquisition- </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> related </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contingent </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Consideration </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Liabilities: </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance at December 31, 2019 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,430,000 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Change in fair value recorded in earnings </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 30,000 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance at March 31, 2020 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,460,000 </td> </tr> </table></div>   <div /></div> </div> 0.03 0.10 0.03 0.03 0.03 0.10 500000 2000 55398 55398 12000 12000 5357 4401 10714 88928 3991 15800000

<div> <div> 8. Accrued Liabilities Accrued expenses consist of the following: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Payroll and related costs </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 190,596 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 346,244 </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62,781 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12,075 </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Legal fees </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,500 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,354 </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued taxes </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 74,357 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 74,357 </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 83,608 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 58,606 </td> </tr> <tr> <td valign="bottom" style="width:75.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total accrued expenses </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 412,842 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 493,636 </td> </tr> </table></div>   <div /></div> </div>

491557

850066

493636

412842

97651006

104459486

17506

8246

69516

141956

107998

9013

3184

17770

3991

2597860

107998

41271

3184

16839

2428568

20432607

23270124

14388665

17307550

100000

30000

6.5

19.60

2430000

2460000

13922972

13900000

16000000

16047669

<div> <div> Cash   As of March 31, 2020 and December 31, 2019, cash was $16.0 million and $13.9 million, respectively, consisting of checking accounts held at U.S. and Canadian commercial banks. Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced losses related to these balances. <div /></div> </div>

2832429

1682606

13922972

16047669

-1149823

2124697

2380.00

952.00

700.00

108.50

107998

<div> <div> 11. Commitments and Contingencies   Contractual Obligations In August 2014, we entered into a lease for corporate office space in Edison, New Jersey. In December 2017, we entered an amendment to the lease for corporate office space in Edison, New Jersey expanding the office footprint and extending the lease for an approximate 5-year period. In May 2018, we entered into a 3 year lease for office equipment to be used at our corporate office space in Edison, New Jersey. In October 2019, we entered into a 3 year lease for office and research laboratory space in Edmonton, Canada. Prior to signing this lease, the space was previously on a month to month basis. Legal Proceedings We are involved in legal proceedings of various types. Significant judgment is required to determine both the likelihood and the estimated amount of a loss related to such matters. Additionally, while any litigation contains an element of uncertainty, we have at this time no reason to believe that the outcome of such proceedings or claims will have a material adverse effect on our condensed consolidated financial condition or results of operations. Leases We account for leases in accordance with ASC Topic 842, Leases, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) the customer has the right to control the use of the identified asset. Operating leases where we are the lessee are included under the caption “Right of Use Assets” on our condensed consolidated balance sheets. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. Key estimates and judgments include how we determine (1) the discount rate used to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments. The Right-Of-Use (“ROU”) asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. We adopted ASC 842 in the first quarter of 2019 using an alternative modified retrospective approach, in which prior periods will not be restated. As a result of the adoption, as of January 1, 2019, we recognized an operating lease liability of $0.8 million based on the present value of the minimum rental payments of the leases and a corresponding ROU asset of $0.8 million. As of March 31, 2020, the ROU assets are $0.7 million, the current lease liabilities are $0.3 million, and the non-current lease liabilities are $0.5 million. The discount rate used to account for our operating leases under ASC 842 is our estimated incremental borrowing rate of 6.5%. Rent expense for the three months ended March 31, 2020 and 2019 was $0.1 and $0.1, respectively. The weighted average remaining term of our noncancelable operating leases is 2.88 years. Future minimum rental payments under our noncancelable operating leases at March 31, 2020 is as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 210,255 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 282,176 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 267,425 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2023 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 53,902 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2024 and thereafter </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 813,758 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Present value adjustment </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (68,283) </td> </tr> <tr> <td valign="top" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Lease liability at March 31, 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 745,475 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div> Employment Agreements   We have employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control, termination without cause or retirement, occur. <div /></div> </div>

<div> <div> Contingencies   In the normal course of business, we are subject to loss contingencies, such as legal proceedings and claims arising out of our business that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters. In accordance with ASC Topic 450, Accounting for Contingencies, (“ASC 450”), we record accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. In accordance with this guidance, we do not recognize gain contingencies until realized. <div /></div> </div>

0.0001

120000000

3760255

6074122

3760255

6074122

375

606

46000

1200000

147

3000000

81585

1353

400000

1100000

149918

149917

11882

176585

18752

4641

6527

5623

15303

4400000

1500000

4000000

5623

15303

<div> <div> Derivative Financial Instruments    We have issued common stock warrants in connection with the execution of certain equity financings. The fair value of the warrants, which were deemed to be derivative instruments based on certain contingent put features, was recorded as a derivative liability under the provisions of ASC Topic 815 Derivatives and Hedging (“ASC 815”) upon issuance. Subsequently, the liability is adjusted to fair value as of the end of each reporting period and the changes in the fair value of derivative liabilities are recorded in the statements of operations under the caption “Change in fair value of derivative financial instruments—warrants.” See Note 5 for additional information.   The fair value of the warrants, issued in connection with the October 2015, April 2016, and April 2018 common stock offerings were deemed to be derivative instruments due to certain contingent put feature, was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.   The warrants, issued in connection with the July 2018 Rights Offering (See Note 5) are deemed to be derivative instruments since if we do not maintain an effective registration statement, we are obligated to deliver registered shares upon exercise and settlement of the warrant because there are further registration and prospectus delivery requirements that are outside our control. Therefore, the fair value of the warrants was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.   The fair value of warrants was affected by changes in inputs to the Black-Scholes option pricing model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. This model uses Level 3 inputs, including stock price volatility, in the fair value hierarchy established by ASC 820 Fair Value Measurement. At March 31, 2020 and December 31, 2019, the fair value of all warrants was $15,303 and $5,623, respectively, which are classified as a long-term derivative liability on our condensed consolidated balance sheets. <div /></div> </div>

<div> <div> 9. Accounting for Share‑Based Payments On June 3, 2013, we adopted the 2013 Equity Incentive Plan (the “Plan”). Stock options granted under the Plan typically will vest after three years of continuous service from the grant date and will have a contractual term of ten years. Stockholder and Board approval was obtained on December 2, 2014 to increase the number of authorized shares to 11,607 and on December 14, 2016  Stockholder and Board approval was obtained to increase the number of authorized shares to 13,750. Stockholder and Board approval was obtained on February 21, 2018 to increase the number of authorized shares to 40,535. As of March 31, 2020, we had 0 shares of common stock available for grant under the Plan.  We classify stock-based compensation expense in our condensed consolidated statement of operations in the same way the award recipient's payroll costs are classified or in which the award recipients' service payments are classified. We recorded stock-based compensation expense as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> </tr> <tr> <td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, </td> </tr> <tr> <td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,910 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,365 </td> </tr> <tr> <td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,336 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,141 </td> </tr> <tr> <td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation expense </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8,246 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 17,506 </td> </tr> <tr> <td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div> A summary of stock option activity and of changes in stock options outstanding under the Plan is presented below: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.72%;"> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Per Share </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Per Share </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual Term </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance outstanding, December 31, 2019 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,271 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> - </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 194.83 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43,182 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.42 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> - </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cancelled </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> - </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance outstanding, March 31, 2020 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,271 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> - </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 209.07 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.33 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested awards and those expected to vest at March 31, 2020 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 39,913 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> - </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 216.06 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8.30 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested and exercisable at March 31, 2020 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,415 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> - </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 586.07 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.52 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> </table></div> There were no options granted to employees during the three months ended March 31, 2020 and 2019, respectively. The total fair value of the shares vested during the three months ended March 31, 2020 was de minimis. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of our common stock for those stock options that had exercise prices lower than the fair value of our common stock. As of March 31, 2020, the unrecognized compensation cost related to non-vested stock options outstanding, net of expected forfeitures, was approximately $0.1 million to be recognized over a weighted-average remaining vesting period of approximately 2.7 years. The following weighted-average assumptions are used in the Black-Scholes valuation model to estimate fair value of stock option awards when granted to employees. Risk‑free interest rate—Based on the daily yield curve rates for U.S. Treasury obligations with maturities which correspond to the expected term of our stock options. Dividend yield— We have not paid any dividends on our common stock since inception and do not anticipate paying dividends on our common stock in the foreseeable future. Expected volatility—Because we have a limited trading history in our common stock, we base expected volatility on that of comparable public development stage biotechnology companies. Expected term—The expected option term represents the period that stock‑based awards are expected to be outstanding based on the simplified method provided in SAB No. 107, which SAB No. 107, options are considered to be “plain vanilla” if they have the following basic characteristics: (i) granted “at‑the‑money”; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non‑transferable and non‑hedgeable. In December 2007, the SEC issued SAB No. 110, Share‑Based Payment, (“SAB No. 110”). SAB No. 110 was effective January 1, 2008 and expresses the views of the Staff of the SEC with respect to extending the use of the simplified method, as discussed in SAB No. 107, in developing an estimate of the expected term of “plain vanilla” share options in accordance with ASC 718. We will use the simplified method until we have the historical data necessary to provide a reasonable estimate of expected life in accordance with SAB No. 107, as amended by SAB No. 110. For the expected term, we have “plain‑vanilla” stock options, and therefore used a simple average of the vesting period and the contractual term for options granted as permitted by SAB No. 107. Forfeitures—ASC 718 allows for the election of forfeitures to be estimated at the time of grant and revised if necessary, in subsequent periods if actual forfeitures differ from those estimates. At April 1, 2016, we determined that we had sufficient history of issuing stock options and decreased our estimated forfeiture rate from 10%, which was based on the historical experience of our former parent, to 3%, which is our actual historical forfeiture rate. The forfeiture rate was 10% through the end of the 3rd fiscal quarter ended March 31, 2016 and was the adjusted to 3% through the end of the fiscal year June 30, 2016 based on the aforementioned historical analysis. The forfeiture rate was 3% for the three months ended March 31, 2020 and 2019. We will continue to analyze the forfeiture rate on at least an annual basis or when there are any identified triggers that would justify immediate review. <div /></div> </div>

24321

-8.03

-0.97

<div> <div> Net loss per share   Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC 260”) for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. <div /></div> </div>

<div> <div> 10. Loss per Share Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC 260”) for all periods presented. In accordance with ASC 260, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. In addition, the net loss attributable to common stockholders’ is adjusted for the preferred stock deemed dividends related accretion of beneficial conversion feature and other discount on this instrument for the periods in which the preferred stock is outstanding. The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Basic and diluted net (loss) income per common share </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Numerator: </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (4,226,617) </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,983,711) </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Preferred stock deemed dividend </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (24,321) </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss attributable to common stockholders </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (4,226,617) </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,008,032) </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Denominator: </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted average common shares outstanding </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,345,699 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 250,126 </td> </tr> <tr> <td valign="middle" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Net loss per share of common stock—basic and diluted </td> <td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (0.97) </td> <td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (8.03) </td> </tr> <tr> <td valign="middle" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div> The following outstanding securities at March 31, 2020 and 2019 have been excluded from the computation of basic and diluted weighted shares outstanding, as they would have been anti-dilutive:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:24.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:24.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common shares issuable upon conversion of Series A preferred stock </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,184 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,184 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common shares issuable upon conversion of Series C preferred stock </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 16,839 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 17,770 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,271 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9,013 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrants – liability classified </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 107,998 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 107,998 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants – equity classified </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,428,568 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,991 </td> </tr> <tr> <td valign="top" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,597,860 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 141,956 </td> </tr> </table></div> The liability and equity classified warrants disclosed above have been excluded from the computation of basic and diluted earnings per share because the exercise price of the warrants exceeds the average market price of our common stock for the period they were outstanding. <div /></div> </div>

346244

190596

P2Y8M12D

100000

-195917

9680

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.77 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.06 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.31 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.33 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 117 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 69 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.77 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.01 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.26 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.33 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 130 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 75 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.77 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.25 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.50 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.33 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 116 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 65 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.77 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.53 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.78 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.33 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 144 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 72 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 6. Fair Value Measurements The following table presents our liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy at March 31, 2020 and December 31, 2019. <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active Markets for </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">  Identical Assets </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> and Liabilities </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair value </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> As of March 31, 2020: </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contingent consideration </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,460,000 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,460,000 </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Derivative liabilities related to warrants </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15,303 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15,303 </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> As of December 31, 2019: </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contingent consideration </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,430,000 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,430,000 </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Derivative liabilities related to warrants </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,623 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,623 </td> </tr> </table></div>   The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities- warrants in our condensed consolidated statement of operations. See Note 5 for a rollfoward of the derivative liability for the three months ended March 31, 2020. The financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we  review the assets and liabilities that are subject to ASC 815-40. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.   Contingent consideration was recorded for the acquisition of Ciclofilin on June 10, 2016. The contingent consideration represented the acquisition date fair value of potential future payments, to be paid in cash and our stock, upon the achievement of certain milestones and was estimated based on a probability-weighted discounted cash flow model utilizing a discount rate of 6.5% and a stock price of $19.60. We completed the first segment of our Phase 1 clinical activities for CRV431 in October 2018 wherein we reached a major clinical milestone of positive data from a Phase I trial of CRV431 in humans. This achievement triggered the first milestone payment, as stated in the Merger Agreement for the acquisition of Ciclofilin Pharmaceuticals, Inc. (Ciclofilin ) and in the fourth quarter of 2018, we paid a related milestone payment of $1,000,000 and issued 1,439 shares of our common stock with a fair value of $55,398, representing 2.5% of our issued and outstanding common stock as of June, 2016, to the Ciclofilin shareholders. As of March 31, 2020, due to the uncertainty in the timing of the clinical development of the associated product candidate, the entire balance is classified as a non-current liability. The following table presents the change in fair value of the contingent consideration for the three months ended March 31, 2020.   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Acquisition- </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> related </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contingent </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Consideration </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Liabilities: </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance at December 31, 2019 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,430,000 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Change in fair value recorded in earnings </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 30,000 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance at March 31, 2020 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,460,000 </td> </tr> </table></div>   <div /></div> </div>

30000

2430000

2460000

-9680

-5623

-15303

<div> <div> Fair Value of Financial Instruments   Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.   ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</td></tr></table></div>   To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.   Financial instruments consist of cash and accounts payable, short-term debt, derivative instruments — warrants, convertible debt and contingent consideration. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short term nature, except for derivative instruments — warrants and contingent consideration, which were marked to market at the end of each reporting period. See Note 5 for additional information of the fair value of the derivative liabilities. We recorded contingent consideration from the 2016 acquisition of Ciclofilin, which is required to be carried at fair value. See Note 6 for additional information on the fair value of the contingent consideration. <div /></div> </div>

<div> <div> Foreign Exchange   The functional currency of Hepion Pharmaceuticals, Inc. and ContraVir Research Inc. is the U.S. dollar. The functional currency of Hepion Research Corp. is the Canadian dollar. Our reporting currency is the U.S. dollar. The assets and liabilities of Ciclofilin are translated into U.S. dollars using period-end exchange rates; income and expenses are translated using the average exchange rates for the reporting period. Unrealized foreign currency translation adjustments are deferred in accumulated other comprehensive loss, a separate component of shareholders’ equity. The amount of currency translation adjustment was immaterial at March 31, 2020 and December 31, 2019.   Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in other foreign exchange (gain) loss within the consolidated statements of operations. The impact of foreign exchange gains (losses) was immaterial at March 31, 2020 and December 31, 2019.   <div /></div> </div>

1403660

1549606

1870924

<div> <div> 7. Indefinite-lived Intangible Assets and Goodwill   IPR&D   Our IPR&D asset consisted of the following at:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Indefinite-lived </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intangible Asset </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> CRV431 balance at December 31, 2019 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,190,000 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value during the three months ended March 31, 2020 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> CRV431 balance at March 31, 2020 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,190,000 </td> </tr> </table></div>   No impairment losses were recorded on IPR&D during the three months ended March 31, 2020 and 2019.   Goodwill   The table below provides a roll-forward of our goodwill balance:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amount </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Goodwill balance at December 31, 2019 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,870,924 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Changes during the three months ended March 31, 2020 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Goodwill balance at March 31, 2020 </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,870,924 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Goodwill and In-Process Research & Development   In accordance with ASC Topic 350, Intangibles — Goodwill and Other (“ASC Topic 350”), goodwill and acquired IPR&D are determined to have indefinite lives and, therefore, are not amortized. Instead, they are tested for impairment annually, in our fourth quarter, and between annual tests if we become aware of an event or a change in circumstances that would indicate the carrying value may be impaired.   In January 2017, the Financial  Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment, which eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable.   The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. We adopted ASU 2017-04 on January 1, 2020, and the adoption of this standard did not have a material effect on our condensed condolidated financial statements.   Goodwill relates to amounts that arose in connection with the acquisition of Ciclofilin. Goodwill represents the excess of the purchase price over the fair value of the net assets acquired when accounted for using the acquisition method of accounting for business combinations. As a result of the COVID-19 pandemic, we performed a qualitative assessment of goodwill and determined that it was not more likely than not that the fair value of our reporting was less than its carrying value. There was no impairment of goodwill for the three months ended March 31, 2020 and 2019.   IPR&D acquired in a business combination is capitalized as indefinite-lived assets on our condensed consolidated balance sheets at the acquisition-date fair value. Once the project is completed, the carrying value of the IPR&D is reclassified to other intangible assets, net and is amortized over the estimated useful life of the asset. Post-acquisition research and development expenses related to the IPR&D projects are expensed as incurred. The projected discounted cash flow models used to estimate the fair values of our IPR&D assets, acquired in connection with the Ciclofilin acquisition, reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including: (i) probability of successfully completing clinical trials and obtaining regulatory approval; (ii) market size, market growth projections, and market share; (iii) estimates regarding the timing of and the expected costs to advance clinical programs to commercialization; (iv) estimates of future cash flows from potential product sales; and (v) a discount rate. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The use of different inputs and assumptions could increase or decrease our estimated discounted future cash flows, the resulting estimated fair values and the amounts of related impairments, if any.   If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to the revised fair value with the related impairment charge recognized in the period in which the impairment occurs. If the carrying value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs.   As a result of the COVID-19 pandemic, we performed a qualitative assessment of IPR&D and determined that it was not more likely than not that the asset was impaired. There was no impairment of IPR&D for the three months ended March 31, 2020 and 2019. <div /></div> </div>

-1983711

-4226617

1000000

<div> <div> Income Taxes   We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We reduce the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that we will not realize some or all of the deferred tax asset. We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more-likely-than-not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.   In April 2019, we transferred state net operating loss tax credits and received approximately $1.0 million in connection with the sale of the state net operating losses to a third party recorded as an income tax benefit in the consolidated statement of operations. We received approval for the sale of net operating losses through participation in the New Jersey Technology Business Tax Certificate Transfer (NOL) Program. <div /></div> </div>

-46188

277715

107821

783513

3190000

98287

8953

813758

53902

267425

282176

210255

68283

P5Y

P3Y

4247015

4502438

20432607

23270124

1251889

1536001

0.0098

946453

6800465

-37849

2194

-2058427

-4677962

-1983711

-4226617

-2008032

-4226617

<div> <div> 4. Recent Accounting Pronouncements   In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes. This guidance will be effective for us in the first quarter of 2021 on a prospective basis, and early adoption is permitted. We are currently evaluating the impact of the new guidance on our condensed consolidated financial statements.   In August of 2018, the FASB issued ASU 2018-13 — Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends disclosure requirements on fair value measurements in Topic 820. This amendment modifies the valuation process of fair value measurements by removing the disclosure requirements for the valuation processes for Level 3 fair value measurements, clarifying the timing of the measurement uncertainty disclosure, and including the changes in unrealized gains and losses for recurring Level 3 fair value measurements in other comprehensive income if held at the end of the reporting period. It also allows the disclosure of other quantitative information in lieu of the weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019 and should be applied prospectively for the most recent period presented in the initial fiscal year of adoption. We adopted this standard on January 1, 2020 and the impact that this guidance had on our condensed consolidated financial statements was immaterial.   <div /></div> </div>

1921700

4186937

-1921700

-4186937

100000

800000

745475

266696

273093

300000

540751

472382

500000

800000

797913

724916

700000

0.065

P2Y10M17D

58606

83608

127939

128289

1000000

1500000

700000

500000

900000

37849

24321

1000

85581

1827

85581

1827

85581

1827

85581

1827

855808

861033

855808

861033

465693

1259881

6788465

6800000

11300000

4500000

9900000

15000000

7000000

12000000

2194

12000

57166

48445

<div> <div> Property, equipment and depreciation   As of March 31, 2020 and December 31, 2019, we had $48,445 and $57,166, respectively, of property and equipment, consisting primarily of computer equipment, furniture and fixtures. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight‑line method based on the estimated useful lives of the related assets. The estimated useful lives of the depreciable assets are 3 to 5 years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives, or the remaining term of the lease, whichever is shorter. Depreciation expense for the the three months ended March 31, 2020 and 2019  was $6,527 and $4,641 respectively. Expenditures for repairs and maintenance are charged to operations as incurred. We will periodically evaluate whether current events or circumstances indicate that the carrying value of our depreciable assets may not be recoverable. There were no adjustments to the carrying value of property and equipment at March 31, 2020 or December 31, 2019. <div /></div> </div>

P5Y

P3Y

303547

518040

2637331

<div> <div> Research and Development   Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, license costs, regulatory and scientific consulting fees, as well as contract research, insurance and FDA consultants, are accounted for in accordance with ASC Topic 730, Research and Development, (“ASC 730”). Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.   We do not currently have any commercial biopharmaceutical products and does not expect to have such for several years, if at all. Accordingly, our research and development costs are expensed as incurred. While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that we have no history of successful commercialization of product candidates to base any estimate of the number of future periods that would be benefited.   Also as prescribed by ASC 730, non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts would be recognized as an expense. At March 31, 2020 and December 31, 2019, we had prepaid research and development costs of $1.1 million and $0.4 million, respectively. <div /></div> </div>

-83182630

-87409247

0.025

<div> <div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:24.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:24.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common shares issuable upon conversion of Series A preferred stock </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,184 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,184 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common shares issuable upon conversion of Series C preferred stock </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 16,839 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 17,770 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,271 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9,013 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrants – liability classified </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 107,998 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 107,998 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants – equity classified </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,428,568 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,991 </td> </tr> <tr> <td valign="top" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,597,860 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 141,956 </td> </tr> </table></div>   <div /></div> </div>

<div> <div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Basic and diluted net (loss) income per common share </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Numerator: </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (4,226,617) </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,983,711) </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Preferred stock deemed dividend </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (24,321) </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss attributable to common stockholders </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (4,226,617) </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,008,032) </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Denominator: </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted average common shares outstanding </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,345,699 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 250,126 </td> </tr> <tr> <td valign="middle" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Net loss per share of common stock—basic and diluted </td> <td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (0.97) </td> <td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (8.03) </td> </tr> <tr> <td valign="middle" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active Markets for </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">  Identical Assets </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> and Liabilities </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair value </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> As of March 31, 2020: </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contingent consideration </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,460,000 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,460,000 </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Derivative liabilities related to warrants </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15,303 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15,303 </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> As of December 31, 2019: </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contingent consideration </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,430,000 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,430,000 </td> </tr> <tr> <td valign="bottom" style="width:42.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Derivative liabilities related to warrants </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,623 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,623 </td> </tr> </table></div>   <div /></div> </div>

<div> <div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.72%;"> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Per Share </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Per Share </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual Term </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance outstanding, December 31, 2019 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,271 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> - </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 194.83 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43,182 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.42 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> - </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cancelled </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> - </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance outstanding, March 31, 2020 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,271 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> - </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 209.07 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.33 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested awards and those expected to vest at March 31, 2020 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 39,913 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> - </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 216.06 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8.30 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:47.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested and exercisable at March 31, 2020 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,415 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> - </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,452.80 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 586.07 </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.52 </td> <td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Segment Information   Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker views our operations and manages the business in one segment.   <div /></div> </div>

17506

10365

7141

8246

5910

2336

P3Y

P10Y

11607

13750

40535

14415

586.07

P6Y6M7D

43182

41271

194.83

209.07

P8Y5M1D

P8Y3M29D

39913

216.06

P8Y3M18D

<div> <div> Share-based payments   ASC Topic 718 “Compensation—Stock Compensation” (“ASC 718”) requires companies to measure the cost of employee and non-employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award. Generally, we issue stock options with only service-based vesting conditions and record the expense for awards using the straight-line method.   The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. We have a limited trading history in our common stock and lacks company-specific historical and implied volatility information. Therefore, the estimated expected stock volatility is based on the historical volatility of a publicly traded set of peer companies until such time as we have adequate historical data regarding the volatility of our own traded stock price. The expected term of stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future.   <div /></div> </div>

3.24

2452.80

119.70

5.36

1.77

247013

85581

1974

306748

85581

1928

3760255

85581

1827

6074122

85581

1827

<div> <div> 3. Summary of Significant Accounting Policies   Use of Estimates   The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.   Our significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2019 included in our Form 10-K. Since the date of such consolidated financial statements, there have been no changes to our significant accounting policies.   Cash   As of March 31, 2020 and December 31, 2019, cash was $16.0 million and $13.9 million, respectively, consisting of checking accounts held at U.S. and Canadian commercial banks. Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced losses related to these balances.   Fair Value of Financial Instruments   Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.   ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.</td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</td></tr></table></div>   To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.   Financial instruments consist of cash and accounts payable, short-term debt, derivative instruments — warrants, convertible debt and contingent consideration. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short term nature, except for derivative instruments — warrants and contingent consideration, which were marked to market at the end of each reporting period. See Note 5 for additional information of the fair value of the derivative liabilities. We recorded contingent consideration from the 2016 acquisition of Ciclofilin, which is required to be carried at fair value. See Note 6 for additional information on the fair value of the contingent consideration.   Derivative Financial Instruments    We have issued common stock warrants in connection with the execution of certain equity financings. The fair value of the warrants, which were deemed to be derivative instruments based on certain contingent put features, was recorded as a derivative liability under the provisions of ASC Topic 815 Derivatives and Hedging (“ASC 815”) upon issuance. Subsequently, the liability is adjusted to fair value as of the end of each reporting period and the changes in the fair value of derivative liabilities are recorded in the statements of operations under the caption “Change in fair value of derivative financial instruments—warrants.” See Note 5 for additional information.   The fair value of the warrants, issued in connection with the October 2015, April 2016, and April 2018 common stock offerings were deemed to be derivative instruments due to certain contingent put feature, was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.   The warrants, issued in connection with the July 2018 Rights Offering (See Note 5) are deemed to be derivative instruments since if we do not maintain an effective registration statement, we are obligated to deliver registered shares upon exercise and settlement of the warrant because there are further registration and prospectus delivery requirements that are outside our control. Therefore, the fair value of the warrants was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.   The fair value of warrants was affected by changes in inputs to the Black-Scholes option pricing model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. This model uses Level 3 inputs, including stock price volatility, in the fair value hierarchy established by ASC 820 Fair Value Measurement. At March 31, 2020 and December 31, 2019, the fair value of all warrants was $15,303 and $5,623, respectively, which are classified as a long-term derivative liability on our condensed consolidated balance sheets.   Property, equipment and depreciation   As of March 31, 2020 and December 31, 2019, we had $48,445 and $57,166, respectively, of property and equipment, consisting primarily of computer equipment, furniture and fixtures. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight‑line method based on the estimated useful lives of the related assets. The estimated useful lives of the depreciable assets are 3 to 5 years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives, or the remaining term of the lease, whichever is shorter. Depreciation expense for the the three months ended March 31, 2020 and 2019  was $6,527 and $4,641 respectively. Expenditures for repairs and maintenance are charged to operations as incurred. We will periodically evaluate whether current events or circumstances indicate that the carrying value of our depreciable assets may not be recoverable. There were no adjustments to the carrying value of property and equipment at March 31, 2020 or December 31, 2019.   Goodwill and In-Process Research & Development   In accordance with ASC Topic 350, Intangibles — Goodwill and Other (“ASC Topic 350”), goodwill and acquired IPR&D are determined to have indefinite lives and, therefore, are not amortized. Instead, they are tested for impairment annually, in our fourth quarter, and between annual tests if we become aware of an event or a change in circumstances that would indicate the carrying value may be impaired.   In January 2017, the Financial  Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment, which eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable.   The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. We adopted ASU 2017-04 on January 1, 2020, and the adoption of this standard did not have a material effect on our condensed condolidated financial statements.   Goodwill relates to amounts that arose in connection with the acquisition of Ciclofilin. Goodwill represents the excess of the purchase price over the fair value of the net assets acquired when accounted for using the acquisition method of accounting for business combinations. As a result of the COVID-19 pandemic, we performed a qualitative assessment of goodwill and determined that it was not more likely than not that the fair value of our reporting was less than its carrying value. There was no impairment of goodwill for the three months ended March 31, 2020 and 2019.   IPR&D acquired in a business combination is capitalized as indefinite-lived assets on our condensed consolidated balance sheets at the acquisition-date fair value. Once the project is completed, the carrying value of the IPR&D is reclassified to other intangible assets, net and is amortized over the estimated useful life of the asset. Post-acquisition research and development expenses related to the IPR&D projects are expensed as incurred. The projected discounted cash flow models used to estimate the fair values of our IPR&D assets, acquired in connection with the Ciclofilin acquisition, reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including: (i) probability of successfully completing clinical trials and obtaining regulatory approval; (ii) market size, market growth projections, and market share; (iii) estimates regarding the timing of and the expected costs to advance clinical programs to commercialization; (iv) estimates of future cash flows from potential product sales; and (v) a discount rate. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The use of different inputs and assumptions could increase or decrease our estimated discounted future cash flows, the resulting estimated fair values and the amounts of related impairments, if any.   If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to the revised fair value with the related impairment charge recognized in the period in which the impairment occurs. If the carrying value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs.   As a result of the COVID-19 pandemic, we performed a qualitative assessment of IPR&D and determined that it was not more likely than not that the asset was impaired. There was no impairment of IPR&D for the three months ended March 31, 2020 and 2019.   Income Taxes   We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We reduce the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that we will not realize some or all of the deferred tax asset. We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more-likely-than-not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.   In April 2019, we transferred state net operating loss tax credits and received approximately $1.0 million in connection with the sale of the state net operating losses to a third party recorded as an income tax benefit in the consolidated statement of operations. We received approval for the sale of net operating losses through participation in the New Jersey Technology Business Tax Certificate Transfer (NOL) Program.   Contingencies   In the normal course of business, we are subject to loss contingencies, such as legal proceedings and claims arising out of our business that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters. In accordance with ASC Topic 450, Accounting for Contingencies, (“ASC 450”), we record accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. In accordance with this guidance, we do not recognize gain contingencies until realized.   Research and Development   Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, license costs, regulatory and scientific consulting fees, as well as contract research, insurance and FDA consultants, are accounted for in accordance with ASC Topic 730, Research and Development, (“ASC 730”). Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.   We do not currently have any commercial biopharmaceutical products and does not expect to have such for several years, if at all. Accordingly, our research and development costs are expensed as incurred. While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that we have no history of successful commercialization of product candidates to base any estimate of the number of future periods that would be benefited.   Also as prescribed by ASC 730, non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts would be recognized as an expense. At March 31, 2020 and December 31, 2019, we had prepaid research and development costs of $1.1 million and $0.4 million, respectively.   Share-based payments   ASC Topic 718 “Compensation—Stock Compensation” (“ASC 718”) requires companies to measure the cost of employee and non-employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award. Generally, we issue stock options with only service-based vesting conditions and record the expense for awards using the straight-line method.   The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. We have a limited trading history in our common stock and lacks company-specific historical and implied volatility information. Therefore, the estimated expected stock volatility is based on the historical volatility of a publicly traded set of peer companies until such time as we have adequate historical data regarding the volatility of our own traded stock price. The expected term of stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future.   Foreign Exchange   The functional currency of Hepion Pharmaceuticals, Inc. and ContraVir Research Inc. is the U.S. dollar. The functional currency of Hepion Research Corp. is the Canadian dollar. Our reporting currency is the U.S. dollar. The assets and liabilities of Ciclofilin are translated into U.S. dollars using period-end exchange rates; income and expenses are translated using the average exchange rates for the reporting period. Unrealized foreign currency translation adjustments are deferred in accumulated other comprehensive loss, a separate component of shareholders’ equity. The amount of currency translation adjustment was immaterial at March 31, 2020 and December 31, 2019.   Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in other foreign exchange (gain) loss within the consolidated statements of operations. The impact of foreign exchange gains (losses) was immaterial at March 31, 2020 and December 31, 2019.   Segment Information   Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker views our operations and manages the business in one segment.   Net loss per share   Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC 260”) for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period.   <div /></div> </div>

1975051

76652839

-76463932

855808

930311

645047

77328219

-78447643

855808

908632

16185592

97651006

375

-83182630

855808

861033

18767686

104459486

606

-87409247

855808

861033

<div> <div> 5. Stockholders’ Equity and Derivative Liability — Warrants   Series A Convertible Preferred Stock   During the period from August 5, 2016 to September 30, 2018, certain holders of our Series A Convertible Preferred Stock elected to convert approximately 1.2 million shares of Series A Convertible Preferred Stock into approximately 3.0 million shares of our common stock. For 2019 and the three months ended March 31, 2020,  no shares of our Series A Convertible Preferred Stock were converted. Series C Convertible Preferred Stock Issuance   On July 3, 2018, we completed a rights offering pursuant to our effective registration statement on Form S-1. We offered for sale units in the rights offering and each unit sold in connection with the rights offering consists of 1 share of our Series C Convertible Preferred Stock, or Series C, and common stock warrants (the “Rights Offering”). Upon completion of the offering, pursuant to the rights offering, we sold an aggregate of 10,826 units at an offering price of $1,000 per unit comprised of 10,826 shares of Series C and 88,928 common stock warrants. We received net proceeds of $9.9 million, after deducting expenses relating to the Rights Offering, including dealer-manager fees and offering expenses, totaling approximately $0.9 million, and excluding any proceeds received upon exercise of any warrants.   The common stock warrants are exercisable at $108.50 per share and subject to adjustments upon the occurrence of certain dilutive events. The warrants expire on the fifth anniversary from their original issuance date. We may redeem the warrants for $0.70 per warrant if our common stock closes above $434.00 per share for ten consecutive trading days provided that we may not do so prior to the first anniversary of the closing of the unit offering. The warrants were sold under a written public offering. If a warrant is exercised during a period where a registration statement is not declared effective, we cannot assert that settlement in unregistered shares is permitted. As a result, the warrants are liability classified and carried at their estimated fair value at each reporting until they are exercised, terminated or otherwise settled.   We determined that the Series C should not be classified as temporary equity due to its lack of senior liquidation preferences and is not redeemable on a fixed or determinable date.   The rights and preferences of the Series C are as follows:   Dividends. Holders of Series C shares are entitled to dividends, if and when declared on shares of common stock, on an “as-converted” basis.   Voting. Subject to certain preferred stock class votes specified in the certificate of designation, the holders of Series C shares shall have no voting rights.   Liquidation. Upon any voluntary or involuntary liquidation, dissolution or winding-up of us, holder of Series C shares shall be entitled to receive the same consideration as the holders of our common stock on an “as converted” basis.   Conversion. Each share of Series C is convertible into common stock at any time at the option of the holder thereof at the conversion price then in effect. The conversion price for the Series C is determined by dividing the stated value of $1,000 per share by $108.50 per share (subject to adjustments upon the occurrence of certain dilutive events).   At any time after the first anniversary of the original issuance date, we may, subject to certain conditions, require the conversion of Series C shares.   The gross proceeds of the offering were first allocated to the warrants based on the fair value of the warrants at that time, with the residual proceeds allocated to the Series C. All offering costs were allocated between the Series C and the warrants. In addition, the placement agent received, as compensation for the transaction, unregistered equity warrants to purchase 3,991 shares of our common stock priced at $119.70 per share. The fair value of the placement agent equity classified warrants was $0.2 million at the time of issuance and $0.1 million was allocated to the Series C and $0.1 million was allocated to the liability classified common stock warrants. All costs allocated to the liability classified warrants were expensed immediately and as a component of general and administrative expenses within our condensed  consolidated statement of operations.   In connection with the issuance of the Series C and liability classified warrants, we recognized the intrinsic value of a beneficial conversion feature of $3.8 million. The beneficial conversion amount was computed as the difference between the Series C effective conversion price and the fair value of our common stock multiplied by that number of shares issuable upon conversion.   As a result of our issuance of convertible preferred shares that included a beneficial conversion feature, we may, upon conversion of the Series C, recognize any unamortized discount resulting from the initial allocation of proceeds issued to the liability classified warrants. During the year ended December 31, 2019, the holders of Series C shares converted 147 shares of Series C into 1,353 shares of common stock. As a result of the conversion, we recognized a preferred stock discount amortization to additional paid in capital of $77,721 as deemed dividends. During the year ended December 31, 2018, the holders of Series C shares converted 8,852 shares of Series C into 81,585 shares of common stock. As a result of the conversion, we recognized a deemed dividend charged to additional paid in capital of $4.7 million associated with the difference between the stated and carrying per share values of the Series C, including a $0.5 million accretion related to issuance costs that had been allocated to the Series C, which have been presented as a component of net loss attributable to common stockholders in our consolidated statement of operations. During the three months ended March 31, 2020, no shares of Series C were converted into common stock.   Beneficial Conversion Feature- Series C Convertible Preferred Stock   Each share of Series C is convertible into shares of common stock, at any time at the option of the holder at a conversion price of $108.50 per share. Based on the guidance in ASC 470-20-20, we determined that a beneficial conversion feature exists, as the effective conversion price for the Series C preferred shares at issuance was less than the fair value of the common stock into which the preferred shares are convertible. A beneficial conversion feature based on the intrinsic value of the date of issuances for the Series C was $3.8 million and the preferred stock was discounted by this amount. The beneficial conversion amount of $3.8 million was then accreted back to the preferred stock as a dividend charged to additional paid in capital as the preferred stock was 100% convertible immediately. The $3.8 million accretion was recorded as a dividend reflected in additional paid in capital and presented as a component of net loss attributable to common stockholders in our consolidated statement of operations for the year ended December 31, 2018.   Common Stock and Warrant Offering   On October 7, 2015, we entered into an underwriting agreement related to the public offering and sale of 8,929 shares of common stock and warrants to purchase up to 5,357 shares of common stock, at a fixed combined price to the public of $1,680 under our prior shelf registration statement on Form S-3. The shares of common stock and warrants were issued separately on October 13, 2015. The warrants are immediately exercisable and will be exercisable for a period of five years from the date of issuance at an exercise price of $2,380.00 per share. There is not, nor is there expected to be, any trading market for the warrants issued in the offering contemplated by the Underwriting Agreement.   The gross proceeds to us were $15.0 million, before deducting the underwriting discount and other offering expenses payable by us of approximately $1.5 million. If the warrants were exercised in full, we would receive additional proceeds of approximately $12.8 million.   If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statements of operations. Upon the issuance of these warrants, the fair value of approximately $4.4 million was recorded as derivative financial instruments liability-warrants.   The fair value of these liability classified warrants was estimated using the Black-Scholes option pricing model. We developed our own assumptions for use in the Black-Scholes option pricing model that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of our common stock, our stock price volatility (stock price volatility of comparable companies prior to 2020), the contractual term of the warrants, risk free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement. The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of March 31, 2020 and December 31, 2019:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.77 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.53 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.78 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.33 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 144 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 72 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   On April 4, 2016, we closed a public offering of 8,803 shares of our common stock and warrants to purchase up to 4,401 shares of common stock, at a fixed combined price to the public of $795.20 under our prior shelf registration statement on Form S-3. The warrants are immediately exercisable and will be exercisable for a period of five years from the date of issuance at an exercise price of $952.00 per share. The gross proceeds to us were $7.0 million, before deducting the underwriting discount and other offering expenses payable by us of approximately $0.7 million. If the warrants were exercised in full, we would receive additional proceeds of approximately $4.2 million.   If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the Fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such Fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statement of operations. Upon the issuance of these warrants, the fair value of approximately $1.5 million was recorded as derivative financial instruments liability-warrants.   The fair value of these liability classified warrants was estimated using the Black-Scholes option pricing model. We developed our own assumptions for use in the Black-Scholes option pricing model that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of our common stock, our stock price volatility (stock price volatility of comparable companies prior to 2020), the contractual term of the warrants, risk free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement. The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of March 31, 2020 and December 31, 2019:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.77 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.01 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.26 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.33 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 130 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 75 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   On April 25, 2017, we closed a public offering of 21,429 shares of our common stock and warrants to purchase up to 10,714 shares of common stock, at a fixed combined price to the public of $560.00 under our prior shelf registration statement on Form S-3. The warrants are immediately exercisable and will be exercisable for a period of five years from the date of issuance at an exercise price of $700.00 per share. The gross proceeds to us were $12.0 million, before deducting the underwriting discount and other offering expenses payable by us of approximately $0.5 million. If the warrants were exercised in full, we would receive additional proceeds of approximately $7.5 million.   If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have  determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statement of operations and comprehensive loss. Upon the issuance of these warrants, the fair value of approximately $4.0 million was recorded as derivative financial instruments liability-warrants.   The fair value of these liability classified warrants were estimated using the Black-Scholes option pricing model. We developed our own assumptions for use in the Black-Scholes option pricing model that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of our common stock, our stock price volatility (stock price volatility of comparable companies prior to 2020), the contractual term of the warrants, risk free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement.   The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of March 31, 2020 and December 31, 2019:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.77 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.06 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.31 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.33 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 117 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 69 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The warrants, issued in connection with the July 2018 Rights Offering are deemed to be derivative instruments since if we do not maintain an effective registration statement, we are obligated to deliver registered shares upon exercise and settlement of the warrant because there are further registration and prospectus delivery requirements that are outside of our control. Therefore, the fair value of the warrants was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the warrants issued, including a fixed term and exercise price.   The fair value of these liability classified warrants were estimated using the Black-Scholes option pricing model. We developed our own assumptions for use in the Black-Scholes option pricing model that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of our common stock, our stock price volatility (stock price volatility of comparable companies prior to 2020), the contractual term of the warrants, risk free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement.   The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of March 31, 2020 and December 31, 2019:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Price of Hepion common stock </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.77 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.36 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected warrant term (years) </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.25 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.50 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.33 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.66 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 116 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 65 </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> </tr> <tr> <td valign="bottom" style="width:71.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:03.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The following table sets forth the components of changes in our derivative financial instruments liability balance for the three months ended March 31, 2020: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Derivative </td> </tr> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Instrument </td> </tr> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Date </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Outstanding </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Liability </td> </tr> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> December 31, 2019 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance of derivative financial instruments liability </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 107,998 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,623 </td> </tr> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value of warrants for the three months ended March 31, 2020 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9,680 </td> </tr> <tr> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> March 31, 2020 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:57.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance of derivative financial instruments liability </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 107,998 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15,303 </td> </tr> </table></div>   Common Stock Offering   On February 12, 2020, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR, Inc., as agent (“B. Riley FBR”), pursuant to which we may offer and sell, from time to time, through B. Riley FBR, shares of our common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $7,000,000 (the “Shares”). The offer and sale of the Shares will be made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-229534) filed by us with the Securities and Exchange Commission (the “SEC”) on February 6, 2019, as amended on February 13, 2019, and declared effective by the SEC on February 19, 2019, as supplemented by a prospectus supplement dated February 12, 2020 and filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to the Sales Agreement, B. Riley FBR may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act, including sales made by means of ordinary brokers’ transactions, including on The Nasdaq Capital Market, at market prices or as otherwise agreed with B. Riley FBR. B. Riley FBR will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the Shares from time to time, based upon instructions from us, including any price or size limits or other customary parameters or conditions we may impose. As of March 31, 2020, we sold 2,311,867 shares of our common stock resulting in net proceeds of $6.8 million under the Sales Agreement. On March 27, 2020, we filed a prospectus supplement to the Form S-3 (File No. 333-229534) pursuant to which we may offer and sell an additional $4.6 million. As of April 30, 2020, we sold an additional 2,950,939 shares of our common stock resulting in net proceeds of $4.5 million under the Sales Agreement. As of April 30, 2020, we sold a total of 5,262,806 shares and received total proceeds of $11.3 million from the “at the market offerings”. <div /></div> </div>

0.0142857

126094

8852

424

-46

1439

8929

8803

21429

10826

47429

2311867

5262806

2950939

46000

-46000

486283

486278

6788465

6788234

231

74357

<div> <div> Use of Estimates   The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.   Our significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2019 included in our Form 10-K. Since the date of such consolidated financial statements, there have been no changes to our significant accounting policies. <div /></div> </div>

2.31

1.66

1.26

75.00

1.66

3.50

1.66

0.78

1.66

2.06

117

0.33

1.01

130.00

0.33

3.25

116

0.33

0.53

144

0.33

250126

4345699

EX-101.SCH 8 hepa-20200331.xsd EX-101.SCH 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Commitments and Contingencies - Future minimum rental payments under the Company's noncancelable operating leases (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Changes in Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Business Overview link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Basis of Presentation and Going Concern link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Indefinite-lived Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Accounting for Share-Based Payments link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Loss per Share link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Stockholder’s Equity and Derivative Liability - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Indefinite-lived Intangible Assets and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Accounting for Share-Based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Business Overview (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Basis of Presentation and Going Concern - Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Basis of Presentation and Going Concern - PPP Loan (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Summary of Significant Accounting Policies - Cash (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Summary of Significant Accounting Policies - Derivative financial instruments (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Summary of Significant Accounting Policies - Property, equipment and depreciation (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Summary of Significant Accounting Policies - Goodwill and In-Process Research and Development (Details) link:presentationLink link:calculationLink link:definitionLink 40305 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Preferred stock, Common Stock and Warrant Offering (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Series C Preferred Stock Issuances and Beneficial Conversion Feature (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Common Stock and Warrant Offering (Details) link:presentationLink link:calculationLink link:definitionLink 40504 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Components of changes (Details) link:presentationLink link:calculationLink link:definitionLink 40505 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Common Stock Offering (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Indefinite-lived Intangible Assets and Goodwill - IPR&D (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Indefinite-lived Intangible Assets and Goodwill - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Accounting for Share-Based Payments - Equity Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Accounting for Share-Based Payments - Activity (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Accounting for Share-Based Payments - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Accounting for Share-Based Payments - Weighted-Average Assumptions Used Black Scholes Model (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Commitments and Contingencies - Contractual Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Commitments and Contingencies - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Basis of Presentation and Going Concern - Reverse Stock Split (Details) link:presentationLink link:calculationLink link:definitionLink 40306 - Disclosure - Summary of Significant Accounting Policies - Research and Development (Details) link:presentationLink link:calculationLink link:definitionLink 40307 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 hepa-20200331_cal.xml EX-101.CAL EX-101.DEF 10 hepa-20200331_def.xml EX-101.DEF EX-101.LAB 11 hepa-20200331_lab.xml EX-101.LAB Document and Entity Information Statement [Table] Statement Statement Changes in Stockholders' Equity Document Type Document Period End Date Entity Registrant Name Entity Current Reporting Status Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Entity Interactive Data Current Condensed Consolidated Balance Sheets Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Series A Preferred Stock [Member] Series A Series C Preferred Stock [Member] Series C Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash Cash Prepaid Expense, Current Prepaid expenses Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Operating Lease, Right-of-Use Asset ROU assets Right-of-use assets Indefinite-Lived Intangible Assets (Excluding Goodwill) In-process research and development, ending balance In-process research and development, beginning balance In-process research and development Goodwill Ending balance Beginning balance Goodwill Other Assets Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders’ Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total accrued expenses Operating Lease, Liability, Current Operating lease liabilities, current Current lease liabilities Liabilities, Current Total current liabilities Business Combination, Contingent Consideration, Liability, Noncurrent Contingent consideration Deferred Income Tax Liabilities, Net Deferred tax liability Operating Lease, Liability, Noncurrent Operating lease liabilities, non-current Non-current lease liabilities Derivative Liability, Noncurrent Derivative financial instruments, at estimated fair value-warrants Derivative financial instruments, at estimated fair value—warrants Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 11) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Convertible preferred stock Common Stock, Value, Issued Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 6,074,122 and 3,760,255 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively Additional Paid in Capital, Common Stock Additional paid in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Convertible preferred stock, par value Preferred stock issued (in shares) Convertible preferred stock, shares issued Preferred Stock, Shares Outstanding Convertible preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations and Comprehensive Loss Costs and Expenses [Abstract] Costs and expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense): Amount of expense (income) related to adjustment to fair value of debt. Fair Value Adjustment Of Debt Change in fair value of debt Interest Expense, Debt Interest on debt Amount of expense (income) related to adjustment to fair value of warrant liability and contingent consideration. Fair Value Adjustment Of Warrants and Contingent consideration Change in fair value of derivative instruments-warrants and contingent consideration Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before income taxes Net Income (Loss) Attributable to Parent Net loss Net loss Dividends, Preferred Stock Deemed dividend (see Note 5) Preferred stock deemed dividend Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common shareholders Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted Weighted average common shares outstanding (in shares) Earnings Per Share, Basic and Diluted [Abstract] Net loss per common share: (see Note 10) Earnings Per Share, Basic and Diluted Basic and diluted Net loss per share of common stock-basic and diluted (in dollars per share) Condensed Consolidated Statements of Changes in Stockholders’ Equity Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Preferred Stock [Member] Preferred Stock Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid in Capital Retained Earnings [Member] Accumulated Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Changes in Stockholders' Equity Shares, Outstanding Balance (in shares) Balance (in shares) APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock based compensation expense Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of preferred stock to common Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of preferred stock to common (in shares) The amount of accretion of beneficial conversion feature of preferred stock. Accretion of Beneficial Conversion Feature Accretion of discount Stock Issued During Period, Value, New Issues Issuance of stock Stock Issued During Period, Shares, New Issues Issuance of stock (in shares) Debt redemption fair value Issuance of common stock, debt redemption Debt Conversion, Converted Instrument, Shares Issued Issuance of common stock, debt redemption (in shares) Value of warrants issued as a result of the exercise of warrants. Stock Issued During Period Value Warrants Exercised Warrant exercises Number of warrants exercised during the current period. Stock Issued During Period Shares Warrants Exercised Change in fair value of warrant liability related to warrant exercise (in shares) Warrant exercises (in shares) Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation Stock-based compensation expense Stock-based compensation Depreciation, Depletion and Amortization Depreciation and amortization Fair Value Adjustment of Warrants Change in fair value of derivative instrument-warrants Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Change in fair value of contingent consideration Amount of increase or decrease in the fair value of debt. Change In Fair Value Of Debt Change in fair value of debt Increase (decrease) in noncash interest expense. Non Cash Interest Expense Non-cash interest expense Amortization of Debt Discount (Premium) Amortization of debt discount recorded as interest expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expense Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from disposal of property and equipment Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Proceeds from Issuance of Common Stock Proceeds from the issuance of common stock, net of issuance costs Proceeds from issuance of stock Proceeds from Warrant Exercises Proceeds from the exercise of warrants The cash inflow from the proceeds from issuance of short term debt and common stock. Proceeds from Issuance of Short Term Debt and Common Stock Proceeds from issuance of short term debt and common stock Repayments of Debt Repayment of debt financing Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash at end of period Cash at beginning of period Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplementary disclosure of cash flow information: Interest Paid Cash paid for interest Supplemental Cash Flow Information [Abstract] Supplementary disclosure of non-cash financing activities: Conversion of Stock, Amount Converted Conversion of Series C convertible preferred stock (part of Series C deemed dividend) Preferred Stock, Accretion of Conversion Discount Accretion of Series C preferred stock discount upon conversion Stock Issued Fair value of shares issued Issuance of common stock for debt redemption The amount effected in non-cash financing activities due to adoption of lease accounting. Adoption of Lease Accounting, Non-Cash Financing Activities Adoption of lease accounting No definition available. Business Overview The entire disclosure for Business Overview Footnote. Business Overview Text Block Business Overview Basis of Presentation and Going Concern The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Also includes the entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. Basis Of Presentation And Substantial Doubt about Going Concern [Text Block] Basis of Presentation and Going Concern Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Recent Accounting Pronouncements New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Recent Accounting Pronouncements No definition available. Stockholders' Equity and Derivative Liability - Warrants Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity and Derivative Liability - Warrants Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Indefinite-lived Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Indefinite-lived Intangible Assets and Goodwill Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Liabilities Accounting for Share-Based Payments Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Accounting for Share-Based Payments Loss per Share Earnings Per Share [Text Block] Loss per Share Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Derivatives, Policy [Policy Text Block] Derivative Financial Instruments Property, Plant and Equipment, Policy [Policy Text Block] Property, equipment and depreciation Goodwill and Intangible Assets, Policy [Policy Text Block] Goodwill and In-Process Research & Development Income Tax, Policy [Policy Text Block] Income Taxes Commitments and Contingencies, Policy [Policy Text Block] Contingencies Research and Development Expense, Policy [Policy Text Block] Research and Development Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-based payments Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Exchange Segment Reporting, Policy [Policy Text Block] Segment Information Earnings Per Share, Policy [Policy Text Block] Net loss per share Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Represents the Warrants issued on October 13th, 2015. October132015 [Member] October 13 2015 Represents the Warrants issued on April 4th, 2016. April42016 [Member] April 4 2016 Represents the Warrants issued on April 25th 2017. April252017 [Member] April 25 2017 Represents the warrants issued on July 3rd 2018 July3rd2018 [Member] July 3 2018 Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] Schedule of assumptions used to measure the warrants to remeasure liability Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. Also includes tabular disclosure of reconciliation of beginning and ending balances of financial instrument. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, and Financial Instrument Reconciliation [Table Text Block] Schedule of changes in derivative financial instruments liability balance Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of table represents the liabilities measured and recognized at fair value on a recurring basis Represents tabular information of changes in fair value of contingent consideration. Schedule Of Fair Value For Contingent Consideration Table Text Block Schedule of changes in fair value of contingent consideration Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Schedule of IPR&D asset Schedule of Goodwill [Table Text Block] Schedule of roll-forward of goodwill balance Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued liabilities Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock based compensation expense Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option activity and of changes in stock options outstanding under the Plan Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of basic and diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of outstanding securities excluded from the computation of diluted weighted shares outstanding Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of future minimum rental payments under the Company's noncancelable operating leases Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Business Acquisition [Axis] Business Acquisition Acquiree [Domain] Business Acquisition, Acquiree [Domain] Represents the information pertaining to Ciclofilin Pharmaceuticals, Inc and one wholly-owned subsidiary, Ciclofilin Pharmaceuticals, Inc. Ciclofilin Pharmaceuticals Inc. [Member] Ciclofilin Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Business Overview Payment for Contingent Consideration Liability, Financing Activities Payment of contingent consideration milestone First milestone payment Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Number of shares issued Value of stock issued in lieu of milestone payments. Stock Issued During Period, Value, Issued for Milestone Payments Issuance of common stock in conjunction with milestone payment EX-101.PRE 12 hepa-20200331_pre.xml EX-101.PRE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	Jun. 19, 2020
Document and Entity Information
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Entity Registrant Name	HEPION PHARMACEUTICALS, INC.
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		9,025,061
Entity Central Index Key	0001583771
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Interactive Data Current	Yes

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash	$ 16,047,669	$ 13,922,972
Prepaid expenses	1,259,881	465,693
Total current assets	17,307,550	14,388,665
Property and equipment, net	48,445	57,166
Right-of-use assets	724,916	797,913
In-process research and development	3,190,000	3,190,000
Goodwill	1,870,924	1,870,924
Other assets	128,289	127,939
Total assets	23,270,124	20,432,607
Current liabilities:
Accounts payable	850,066	491,557
Accrued expenses	412,842	493,636
Operating lease liabilities, current	273,093	266,696
Total current liabilities	1,536,001	1,251,889
Contingent consideration	2,460,000	2,430,000
Deferred tax liability	18,752	18,752
Operating lease liabilities, non-current	472,382	540,751
Derivative financial instruments, at estimated fair value-warrants	15,303	5,623
Total liabilities	4,502,438	4,247,015
Commitments and contingencies (Note 11)
Stockholders' equity:
Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 6,074,122 and 3,760,255 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	606	375
Additional paid in capital	104,459,486	97,651,006
Accumulated deficit	(87,409,247)	(83,182,630)
Total stockholders' equity	18,767,686	16,185,592
Total liabilities and stockholders' equity	23,270,124	20,432,607
Series A
Stockholders' equity:
Convertible preferred stock	855,808	855,808
Series C
Stockholders' equity:
Convertible preferred stock	$ 861,033	$ 861,033

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	6,074,122	3,760,255
Common stock, shares outstanding	6,074,122	3,760,255
Series A
Convertible preferred stock, par value	$ 10	$ 10
Convertible preferred stock, shares issued	85,581	85,581
Convertible preferred stock, shares outstanding	85,581	85,581
Series C
Convertible preferred stock, par value	$ 1,000	$ 1,000
Convertible preferred stock, shares issued	1,827	1,827
Convertible preferred stock, shares outstanding	1,827	1,827

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Costs and expenses:
Research and development	$ 2,637,331	$ 518,040
General and administrative	1,549,606	1,403,660
Total operating expenses	4,186,937	1,921,700
Loss from operations	(4,186,937)	(1,921,700)
Other income (expense):
Change in fair value of debt		(59,641)
Interest on debt		(98,287)
Change in fair value of derivative instruments-warrants and contingent consideration	(39,680)	95,917
Loss before income taxes	(4,226,617)	(1,983,711)
Net loss	(4,226,617)	(1,983,711)
Deemed dividend (see Note 5)		(24,321)
Net loss attributable to common shareholders	$ (4,226,617)	$ (2,008,032)
Weighted average common shares outstanding:
Basic and diluted	4,345,699	250,126
Net loss per common share: (see Note 10)
Basic and diluted	$ (0.97)	$ (8.03)

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Stockholders’ Equity - USD ($)	Preferred Stock Series A	Preferred Stock Series C	Common Stock Private placement	Common Stock	Additional Paid in Capital Private placement	Additional Paid in Capital	Accumulated Deficit	Private placement	Total
Balance at Dec. 31, 2018	$ 855,808	$ 930,311		$ 25		$ 76,652,839	$ (76,463,932)		$ 1,975,051
Balance (in shares) at Dec. 31, 2018	85,581	1,974		247,013
Changes in Stockholders' Equity
Net loss							(1,983,711)		(1,983,711)
Stock based compensation expense						17,506			17,506
Conversion of preferred stock to common		$ (46,000)				46,000
Conversion of preferred stock to common (in shares)		(46)		424
Accretion of discount		$ 24,321				(24,321)
Issuance of stock			$ 5		$ 486,278			$ 486,283
Issuance of stock (in shares)			47,429
Issuance of common stock, debt redemption				$ 1		149,917			149,918
Issuance of common stock, debt redemption (in shares)				11,882
Balance at Mar. 31, 2019	$ 855,808	$ 908,632		$ 31		77,328,219	(78,447,643)		645,047
Balance (in shares) at Mar. 31, 2019	85,581	1,928		306,748
Balance at Dec. 31, 2019	$ 855,808	$ 861,033		$ 375		97,651,006	(83,182,630)		16,185,592
Balance (in shares) at Dec. 31, 2019	85,581	1,827		3,760,255
Changes in Stockholders' Equity
Net loss							(4,226,617)		(4,226,617)
Stock based compensation expense						8,246			8,246
Issuance of stock				$ 231		6,788,234			6,788,465
Issuance of stock (in shares)				2,311,867
Warrant exercises						12,000			12,000
Warrant exercises (in shares)				2,000
Balance at Mar. 31, 2020	$ 855,808	$ 861,033		$ 606		$ 104,459,486	$ (87,409,247)		$ 18,767,686
Balance (in shares) at Mar. 31, 2020	85,581	1,827		6,074,122

XML 18 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (4,226,617)	$ (1,983,711)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	8,246	17,506
Depreciation and amortization	6,527	4,641
Change in fair value of derivative instrument-warrants	9,680	(195,917)
Change in fair value of contingent consideration	30,000	100,000
Change in fair value of debt		59,641
Non-cash interest expense		23,906
Amortization of debt discount recorded as interest expense		69,516
Changes in operating assets and liabilities:
Accounts payable and accrued expense	277,715	(46,188)
Prepaid expenses and other assets	(783,513)	(107,821)
Net cash used in operating activities	(4,677,962)	(2,058,427)
Cash flows from investing activities:
Purchase of property and equipment		(37,849)
Proceeds from disposal of property and equipment	2,194
Net cash provided by (used in) investing activities	2,194	(37,849)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs	6,788,465
Proceeds from the exercise of warrants	12,000
Proceeds from issuance of short term debt and common stock		1,250,000
Repayment of debt financing		(303,547)
Net cash provided by financing activities	6,800,465	946,453
Net increase (decrease) in cash	2,124,697	(1,149,823)
Cash at beginning of period	13,922,972	2,832,429
Cash at end of period	$ 16,047,669	1,682,606
Supplementary disclosure of cash flow information:
Cash paid for interest		8,953
Supplementary disclosure of non-cash financing activities:
Conversion of Series C convertible preferred stock (part of Series C deemed dividend)		46,000
Accretion of Series C preferred stock discount upon conversion		24,321
Issuance of common stock for debt redemption		126,094
Adoption of lease accounting		$ 733,374

XML 19 R7.htm IDEA: XBRL DOCUMENT

Business Overview	3 Months Ended
Business Overview	Mar. 31, 2020
Business Overview
Business Overview	1. Business Overview Hepion Pharmaceuticals, Inc. (we, our, or us) is a biopharmaceutical company headquartered in Edison, New Jersey, focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (“HCC”) associated with non-alcoholic steatohepatitis (“NASH”), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 is a cyclophilin inhibitor that targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. CRV431 additionally shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease. On July 18, 2019, we filed a certificate of amendment (the “Certificate of Amendment”) to our certificate of incorporation (the “Certificate”) to change our name from “ContraVir Pharmaceuticals, Inc.” to “Hepion Pharmaceuticals, Inc.” The name change became effective as of July 18, 2019. We are developing CRV431 as our lead molecule. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. To date, in vitro and/or in vivo studies have demonstrated reductions in HBV DNA, HBsAg, HBeAg, inhibition of virus uptake (NTCP transport inhibition), and stimulation of innate immunity. Importantly, in vivo studies in a NASH model of fibrosis and HCC have repeatedly demonstrated CRV431 reduces fibrosis scores and overall liver tumor burden. Hence, CRV431 is a pleiotropic molecule that may not only treat liver disease but may also serve to reduce important risk factors (e.g., HBV) for developing the disease. We have completed a phase 1 study with CRV431 demonstrating safety, tolerability, and pharmacokinetics (PK). CRV431 On May 10, 2018, we submitted an Investigational New Drug Application (“IND”) to the U.S. Food and Drug Administration (“FDA”) to support initiation of our CRV431 HBV clinical development program in the United States and received approval in June 2018. We completed the first segment of Phase 1 clinical activities for CRV431 in October 2018 wherein we reached a major clinical milestone of positive data from a Phase I trial of CRV431 in humans. This achievement triggered the first milestone payment, as stated in the Merger Agreement for the acquisition of Ciclofilin Pharmaceuticals, Inc. (“Ciclofilin”) and we paid a related milestone payment of $1,000,000 and issued 1,439 shares of our common stock with a fair value of $55,398, representing 2.5% of our issued and outstanding common stock as of June 2016, to the Ciclofilin shareholders. On June 17, 2019, we submitted an IND to the FDA to support initiation of our CRV431 NASH clinical development program in the United States and received approval in July 2019.

XML 20 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Going Concern	3 Months Ended
Basis of Presentation and Going Concern	Mar. 31, 2020
Basis of Presentation and Going Concern
Basis of Presentation and Going Concern	2. Basis of Presentation and Going Concern These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet as of December 31, 2019 was derived from the audited annual consolidated financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2019 contained in our Annual Report on Form 10-K. Principles of Consolidation The accompanying condensed consolidated financial statements include our accounts and the accounts of our subsidiaries, Contravir Research Inc. and Hepion Research Corp, which conduct their operations in Canada. All intercompany balances and transactions have been eliminated in consolidation. Reverse Stock Split On May 28, 2019, we effected a 1 for 70 reverse stock split of our common stock. The par value and the number of authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these financial statements have been adjusted retroactively to reflect the reverse stock split. Going Concern As of March 31, 2020, we had $16.0 million in cash, we had an accumulated deficit of $87.4 million, and we had working capital of $15.8 million. For the three months ended March 31, 2020, cash used in operating activities was $4.7 million and we had a net loss of $4.2 million. We have not generated revenue to date and have incurred substantial losses and negative cash flows from operations since our inception. We have historically funded our operations through issuances of convertible debt, common stock and preferred stock. We expect to continue to incur losses for the next several years as we expand our research, development and clinical trials of CRV431. We are unable to predict the extent of any future losses or when we will become profitable, if at all. These condensed consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. We will be required to raise additional capital within the next year to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct business. If we are unable to raise additional capital when required or on acceptable terms, we may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms. COVID-19 Pandemic On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation and its impact on our financial condition, liquidity, operations, suppliers, industry, and workforce. We may experience delays in the conduct of clinical testing of our product candidate. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. The COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidate. The evolving COVID-19 pandemic is also likely to directly or indirectly impact the pace of enrollment in our CRV431 clinical trials for at least the next several months and possibly longer as patients may avoid or may not be able to travel to healthcare facilities and physicians' offices unless due to a health emergency. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a clinical trial, in securing clinical trial agreements with prospective sites with acceptable terms, in obtaining institutional review board approval to conduct a clinical trial at a prospective site, in recruiting patients to participate in a clinical trial, related to the COVID-19 pandemic, or in obtaining sufficient supplies of clinical trial materials. Any delays in completing our clinical trials will increase our costs, slow down our product development, timeliness and approval process and delay our ability to generate revenue. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change and we do not yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. Although we cannot estimate the length or gravity of the impact of the COVID-19 outbreak nor estimate the potential impact to our fiscal year 2020 financial statements at this time, if the pandemic continues, it could have a material adverse effect on our results of future operations, financial position, liquidity, and capital resources, and those of the third parties on which we rely in fiscal year 2020. On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), as amended on June 5, 2020 by the Paycheck Protection Program (“PPP”). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. On April 13, 2020, we were granted a loan (the “Loan”) from JPMorgan Chase Bank, N.A. in the aggregate amount of $176,585, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act. We are continuing to evaluate and examine the impacts the CARES Act may have on our business, results of operations, financial condition or liquidity. The Loan, which was in the form of a Note dated April 13, 2020 issued by us, matures on April 13, 2022 and bears interest at a rate of 0.98% per annum, payable monthly commencing on November 13, 2020. The Note may be prepaid by us at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, rent and utilities. We intend to use the entire Loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. We intend to comply with the loan forgiveness provisions in the legislation; however, there can be no assurance that we will obtain full forgiveness of the loans based on the legislation.

XML 21 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2020

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

3. Summary of Significant Accounting Policies

Use of Estimates

Cash

Fair Value of Financial Instruments

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.

Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.

Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

Derivative Financial Instruments

Property, equipment and depreciation

As of March 31, 2020 and December 31, 2019, we had $48,445 and $57,166, respectively, of property and equipment, consisting primarily of computer equipment, furniture and fixtures. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight‑line method based on the estimated useful lives of the related assets. The estimated useful lives of the depreciable assets are 3 to 5 years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives, or the remaining term of the lease, whichever is shorter. Depreciation expense for the the three months ended March 31, 2020 and 2019 was $6,527 and $4,641 respectively. Expenditures for repairs and maintenance are charged to operations as incurred. We will periodically evaluate whether current events or circumstances indicate that the carrying value of our depreciable assets may not be recoverable. There were no adjustments to the carrying value of property and equipment at March 31, 2020 or December 31, 2019.

Goodwill and In-Process Research & Development

In accordance with ASC Topic 350, Intangibles — Goodwill and Other (“ASC Topic 350”), goodwill and acquired IPR&D are determined to have indefinite lives and, therefore, are not amortized. Instead, they are tested for impairment annually, in our fourth quarter, and between annual tests if we become aware of an event or a change in circumstances that would indicate the carrying value may be impaired.

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment, which eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable.

Income Taxes

We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We reduce the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that we will not realize some or all of the deferred tax asset. We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more-likely-than-not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.

Contingencies

Research and Development

Share-based payments

Foreign Exchange

Segment Information

Net loss per share

XML 22 R10.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements	3 Months Ended
Recent Accounting Pronouncements	Mar. 31, 2020
Recent Accounting Pronouncements
Recent Accounting Pronouncements	4. Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes. This guidance will be effective for us in the first quarter of 2021 on a prospective basis, and early adoption is permitted. We are currently evaluating the impact of the new guidance on our condensed consolidated financial statements. In August of 2018, the FASB issued ASU 2018-13 — Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends disclosure requirements on fair value measurements in Topic 820. This amendment modifies the valuation process of fair value measurements by removing the disclosure requirements for the valuation processes for Level 3 fair value measurements, clarifying the timing of the measurement uncertainty disclosure, and including the changes in unrealized gains and losses for recurring Level 3 fair value measurements in other comprehensive income if held at the end of the reporting period. It also allows the disclosure of other quantitative information in lieu of the weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019 and should be applied prospectively for the most recent period presented in the initial fiscal year of adoption. We adopted this standard on January 1, 2020 and the impact that this guidance had on our condensed consolidated financial statements was immaterial.

XML 23 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Derivative Liability - Warrants

3 Months Ended

Mar. 31, 2020

Stockholders' Equity and Derivative Liability - Warrants

Stockholders' Equity and Derivative Liability - Warrants

5. Stockholders’ Equity and Derivative Liability — Warrants

Series A Convertible Preferred Stock

Series C Convertible Preferred Stock Issuance

We determined that the Series C should not be classified as temporary equity due to its lack of senior liquidation preferences and is not redeemable on a fixed or determinable date.

The rights and preferences of the Series C are as follows:

Dividends. Holders of Series C shares are entitled to dividends, if and when declared on shares of common stock, on an “as-converted” basis.

Voting. Subject to certain preferred stock class votes specified in the certificate of designation, the holders of Series C shares shall have no voting rights.

Liquidation. Upon any voluntary or involuntary liquidation, dissolution or winding-up of us, holder of Series C shares shall be entitled to receive the same consideration as the holders of our common stock on an “as converted” basis.

Conversion. Each share of Series C is convertible into common stock at any time at the option of the holder thereof at the conversion price then in effect. The conversion price for the Series C is determined by dividing the stated value of $1,000 per share by $108.50 per share (subject to adjustments upon the occurrence of certain dilutive events).

At any time after the first anniversary of the original issuance date, we may, subject to certain conditions, require the conversion of Series C shares.

Beneficial Conversion Feature- Series C Convertible Preferred Stock

Common Stock and Warrant Offering

On October 7, 2015, we entered into an underwriting agreement related to the public offering and sale of 8,929 shares of common stock and warrants to purchase up to 5,357 shares of common stock, at a fixed combined price to the public of $1,680 under our prior shelf registration statement on Form S-3. The shares of common stock and warrants were issued separately on October 13, 2015. The warrants are immediately exercisable and will be exercisable for a period of five years from the date of issuance at an exercise price of $2,380.00 per share. There is not, nor is there expected to be, any trading market for the warrants issued in the offering contemplated by the Underwriting Agreement.


	March 31,			December 31,
	2020			2019
Price of Hepion common stock	$	1.77		$	5.36
Expected warrant term (years)		0.53	years		0.78	years
Risk-free interest rate		0.33	%		1.66	%
Expected volatility		144	%		72	%
Dividend yield		—			—

If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the Fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such Fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statement of operations. Upon the issuance of these warrants, the fair value of approximately $1.5 million was recorded as derivative financial instruments liability-warrants.


	March 31,			December 31,
	2020			2019
Price of Hepion common stock	$	1.77		$	5.36
Expected warrant term (years)		1.01	years		1.26	years
Risk-free interest rate		0.33	%		1.66	%
Expected volatility		130	%		75	%
Dividend yield		—			—

If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property (“Fundamental transaction”), then we shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the fundamental transaction and continuing for 90 days, an amount of cash equal to the value of the remaining unexercised portion of the warrant as determined in accordance with the Black-Scholes option pricing model on the date of such fundamental transaction. As a result of these terms, in accordance with the guidance contained in ASC Topic 815-40, we have determined that the warrants issued in connection with this financing transaction must be recorded as derivative liabilities upon issuance and marked to market on a quarterly basis in our condensed consolidated statement of operations and comprehensive loss. Upon the issuance of these warrants, the fair value of approximately $4.0 million was recorded as derivative financial instruments liability-warrants.

The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of March 31, 2020 and December 31, 2019:


	March 31,			December 31,
	2020			2019
Price of Hepion common stock	$	1.77		$	5.36
Expected warrant term (years)		2.06	years		2.31	years
Risk-free interest rate		0.33	%		1.66	%
Expected volatility		117	%		69	%
Dividend yield		—			—

The following assumptions were used to measure the warrants at issuance and to remeasure the liability as of March 31, 2020 and December 31, 2019:


	March 31,			December 31,
	2020			2019
Price of Hepion common stock	$	1.77		$	5.36
Expected warrant term (years)		3.25	years		3.50	years
Risk-free interest rate		0.33	%		1.66	%
Expected volatility		116	%		65	%
Dividend yield		—			—

The following table sets forth the components of changes in our derivative financial instruments liability balance for the three months ended March 31, 2020:


		Number of		Derivative
		Warrants		Instrument
Date	Description	Outstanding		Liability
December 31, 2019	Balance of derivative financial instruments liability		107,998		5,623
	Change in fair value of warrants for the three months ended March 31, 2020		—		9,680
March 31, 2020	Balance of derivative financial instruments liability		107,998	$	15,303

Common Stock Offering

As of March 31, 2020, we sold 2,311,867 shares of our common stock resulting in net proceeds of $6.8 million under the Sales Agreement.

XML 24 R12.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2020

Fair Value Measurements

Fair Value Measurements

6. Fair Value Measurements


			Quoted Prices in		Significant
			Active Markets for		Other		Significant
			Identical Assets		Observable		Unobservable
			and Liabilities		Inputs		Inputs
Description	Fair value		(Level 1)		(Level 2)		(Level 3)
As of March 31, 2020:
Contingent consideration	$	2,460,000	$	—	$	—	$	2,460,000
Derivative liabilities related to warrants	$	15,303	$	—	$	—	$	15,303

As of December 31, 2019:
Contingent consideration	$	2,430,000	$	—	$	—	$	2,430,000
Derivative liabilities related to warrants	$	5,623	$	—	$	—	$	5,623

Contingent consideration was recorded for the acquisition of Ciclofilin on June 10, 2016. The contingent consideration represented the acquisition date fair value of potential future payments, to be paid in cash and our stock, upon the achievement of certain milestones and was estimated based on a probability-weighted discounted cash flow model utilizing a discount rate of 6.5% and a stock price of $19.60. We completed the first segment of our Phase 1 clinical activities for CRV431 in October 2018 wherein we reached a major clinical milestone of positive data from a Phase I trial of CRV431 in humans. This achievement triggered the first milestone payment, as stated in the Merger Agreement for the acquisition of Ciclofilin Pharmaceuticals, Inc. (Ciclofilin ) and in the fourth quarter of 2018, we paid a related milestone payment of $1,000,000 and issued 1,439 shares of our common stock with a fair value of $55,398, representing 2.5% of our issued and outstanding common stock as of June, 2016, to the Ciclofilin shareholders. As of March 31, 2020, due to the uncertainty in the timing of the clinical development of the associated product candidate, the entire balance is classified as a non-current liability. The following table presents the change in fair value of the contingent consideration for the three months ended March 31, 2020.


	Acquisition-
	related
	Contingent
	Consideration
Liabilities:
Balance at December 31, 2019	$	2,430,000
Change in fair value recorded in earnings		30,000
Balance at March 31, 2020	$	2,460,000

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 25 R13.htm IDEA: XBRL DOCUMENT

Indefinite-lived Intangible Assets and Goodwill

3 Months Ended

Mar. 31, 2020

Indefinite-lived Intangible Assets and Goodwill

Indefinite-lived Intangible Assets and Goodwill

7. Indefinite-lived Intangible Assets and Goodwill

IPR&D

Our IPR&D asset consisted of the following at:


	Indefinite-lived
	Intangible Asset
CRV431 balance at December 31, 2019	$	3,190,000
Change in fair value during the three months ended March 31, 2020		—
CRV431 balance at March 31, 2020	$	3,190,000

No impairment losses were recorded on IPR&D during the three months ended March 31, 2020 and 2019.

Goodwill

The table below provides a roll-forward of our goodwill balance:


	Amount
Goodwill balance at December 31, 2019	$	1,870,924
Changes during the three months ended March 31, 2020		—
Goodwill balance at March 31, 2020	$	1,870,924

XML 26 R14.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

3 Months Ended

Mar. 31, 2020

Accrued Liabilities

Accrued Liabilities

8. Accrued Liabilities

Accrued expenses consist of the following:


	March 31,		December 31,
	2020		2019
Payroll and related costs	$	190,596	$	346,244
Research and development		62,781		12,075
Legal fees		1,500		2,354
Accrued taxes		74,357		74,357
Other		83,608		58,606
Total accrued expenses	$	412,842	$	493,636

XML 27 R15.htm IDEA: XBRL DOCUMENT

Accounting for Share-Based Payments

3 Months Ended

Mar. 31, 2020

Accounting for Share-Based Payments

Accounting for Share-Based Payments

9. Accounting for Share‑Based Payments


	Three Months Ended
	March 31,
	2020		2019
General and administrative	$	5,910	$	10,365
Research and development		2,336		7,141
Total stock-based compensation expense	$	8,246	$	17,506

A summary of stock option activity and of changes in stock options outstanding under the Plan is presented below:


							Weighted				Weighted
							Average				Average
	Number of	Exercise Price					Exercise Price		Intrinsic		Remaining
	Options	Per Share					Per Share		Value		Contractual Term
Balance outstanding, December 31, 2019	41,271	$	3.24	-	$	2,452.80	$	194.83	$	43,182	8.42	years
Granted	—		—	-	$	—	$	—	$	—
Forfeited	—		—		$	—	$	—		—
Cancelled	—	$	—	-	$	—	$	—		—
Balance outstanding, March 31, 2020	41,271	$	3.24	-	$	2,452.80	$	209.07	$	—	8.33	years
Vested awards and those expected to vest at March 31, 2020	39,913	$	3.24	-	$	2,452.80	$	216.06	$	—	8.30	years
Vested and exercisable at March 31, 2020	14,415	$	3.24	-	$	2,452.80	$	586.07	$	—	6.52	years

The following weighted-average assumptions are used in the Black-Scholes valuation model to estimate fair value of stock option awards when granted to employees.

Risk‑free interest rate—Based on the daily yield curve rates for U.S. Treasury obligations with maturities which correspond to the expected term of our stock options.

Dividend yield— We have not paid any dividends on our common stock since inception and do not anticipate paying dividends on our common stock in the foreseeable future.

Expected volatility—Because we have a limited trading history in our common stock, we base expected volatility on that of comparable public development stage biotechnology companies.

Expected term—The expected option term represents the period that stock‑based awards are expected to be outstanding based on the simplified method provided in SAB No. 107, which SAB No. 107, options are considered to be “plain vanilla” if they have the following basic characteristics: (i) granted “at‑the‑money”; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non‑transferable and non‑hedgeable.

In December 2007, the SEC issued SAB No. 110, Share‑Based Payment, (“SAB No. 110”). SAB No. 110 was effective January 1, 2008 and expresses the views of the Staff of the SEC with respect to extending the use of the simplified method, as discussed in SAB No. 107, in developing an estimate of the expected term of “plain vanilla” share options in accordance with ASC 718. We will use the simplified method until we have the historical data necessary to provide a reasonable estimate of expected life in accordance with SAB No. 107, as amended by SAB No. 110. For the expected term, we have “plain‑vanilla” stock options, and therefore used a simple average of the vesting period and the contractual term for options granted as permitted by SAB No. 107.

Forfeitures—ASC 718 allows for the election of forfeitures to be estimated at the time of grant and revised if necessary, in subsequent periods if actual forfeitures differ from those estimates. At April 1, 2016, we determined that we had sufficient history of issuing stock options and decreased our estimated forfeiture rate from 10%, which was based on the historical experience of our former parent, to 3%, which is our actual historical forfeiture rate. The forfeiture rate was 10% through the end of the 3rd fiscal quarter ended March 31, 2016 and was the adjusted to 3% through the end of the fiscal year June 30, 2016 based on the aforementioned historical analysis. The forfeiture rate was 3% for the three months ended March 31, 2020 and 2019. We will continue to analyze the forfeiture rate on at least an annual basis or when there are any identified triggers that would justify immediate review.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Loss per Share

3 Months Ended

Mar. 31, 2020

Loss per Share

Loss per Share

10. Loss per Share

The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:



	Three Months Ended
	March 31,
Basic and diluted net (loss) income per common share	2020		2019
Numerator:
Net loss	$	(4,226,617)	$	(1,983,711)
Preferred stock deemed dividend		—		(24,321)
Net loss attributable to common stockholders	$	(4,226,617)	$	(2,008,032)
Denominator:
Weighted average common shares outstanding		4,345,699		250,126
Net loss per share of common stock—basic and diluted	$	(0.97)	$	(8.03)

The following outstanding securities at March 31, 2020 and 2019 have been excluded from the computation of basic and diluted weighted shares outstanding, as they would have been anti-dilutive:



	Three Months Ended
	March 31,
	2020	2019
Common shares issuable upon conversion of Series A preferred stock	3,184	3,184
Common shares issuable upon conversion of Series C preferred stock	16,839	17,770
Stock options	41,271	9,013
Warrants – liability classified	107,998	107,998
Warrants – equity classified	2,428,568	3,991
Total	2,597,860	141,956

XML 29 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2020

Commitments and Contingencies

Commitments and Contingencies

11. Commitments and Contingencies

Contractual Obligations

Legal Proceedings

Leases

We account for leases in accordance with ASC Topic 842, Leases, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) the customer has the right to control the use of the identified asset.


2020	$	210,255
2021		282,176
2022		267,425
2023		53,902
2024 and thereafter		—
Total		813,758
Present value adjustment		(68,283)
Lease liability at March 31, 2020	$	745,475

Employment Agreements

XML 30 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2020

Summary of Significant Accounting Policies

Use of Estimates

Cash

Fair Value of Financial Instruments

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.

Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

Derivative Financial Instruments

Property, equipment and depreciation

As of March 31, 2020 and December 31, 2019, we had $48,445 and $57,166, respectively, of property and equipment, consisting primarily of computer equipment, furniture and fixtures. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight‑line method based on the estimated useful lives of the related assets. The estimated useful lives of the depreciable assets are 3 to 5 years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives, or the remaining term of the lease, whichever is shorter. Depreciation expense for the the three months ended March 31, 2020 and 2019 was $6,527 and $4,641 respectively. Expenditures for repairs and maintenance are charged to operations as incurred. We will periodically evaluate whether current events or circumstances indicate that the carrying value of our depreciable assets may not be recoverable. There were no adjustments to the carrying value of property and equipment at March 31, 2020 or December 31, 2019.

Goodwill and In-Process Research & Development

Income Taxes

Contingencies

Research and Development

XML 31 R19.htm IDEA: XBRL DOCUMENT

Stockholder’s Equity and Derivative Liability - Warrants (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of changes in derivative financial instruments liability balance


		Number of		Derivative
		Warrants		Instrument
Date	Description	Outstanding		Liability
December 31, 2019	Balance of derivative financial instruments liability		107,998		5,623
	Change in fair value of warrants for the three months ended March 31, 2020		—		9,680
March 31, 2020	Balance of derivative financial instruments liability		107,998	$	15,303

October 13 2015

Schedule of assumptions used to measure the warrants to remeasure liability


	March 31,			December 31,
	2020			2019
Price of Hepion common stock	$	1.77		$	5.36
Expected warrant term (years)		0.53	years		0.78	years
Risk-free interest rate		0.33	%		1.66	%
Expected volatility		144	%		72	%
Dividend yield		—			—

April 4 2016

Schedule of assumptions used to measure the warrants to remeasure liability


	March 31,			December 31,
	2020			2019
Price of Hepion common stock	$	1.77		$	5.36
Expected warrant term (years)		1.01	years		1.26	years
Risk-free interest rate		0.33	%		1.66	%
Expected volatility		130	%		75	%
Dividend yield		—			—

April 25 2017

Schedule of assumptions used to measure the warrants to remeasure liability


	March 31,			December 31,
	2020			2019
Price of Hepion common stock	$	1.77		$	5.36
Expected warrant term (years)		2.06	years		2.31	years
Risk-free interest rate		0.33	%		1.66	%
Expected volatility		117	%		69	%
Dividend yield		—			—

July 3 2018

Schedule of assumptions used to measure the warrants to remeasure liability


	March 31,			December 31,
	2020			2019
Price of Hepion common stock	$	1.77		$	5.36
Expected warrant term (years)		3.25	years		3.50	years
Risk-free interest rate		0.33	%		1.66	%
Expected volatility		116	%		65	%
Dividend yield		—			—

XML 32 R20.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Measurements

Schedule of table represents the liabilities measured and recognized at fair value on a recurring basis


			Quoted Prices in		Significant
			Active Markets for		Other		Significant
			Identical Assets		Observable		Unobservable
			and Liabilities		Inputs		Inputs
Description	Fair value		(Level 1)		(Level 2)		(Level 3)
As of March 31, 2020:
Contingent consideration	$	2,460,000	$	—	$	—	$	2,460,000
Derivative liabilities related to warrants	$	15,303	$	—	$	—	$	15,303

As of December 31, 2019:
Contingent consideration	$	2,430,000	$	—	$	—	$	2,430,000
Derivative liabilities related to warrants	$	5,623	$	—	$	—	$	5,623

Schedule of changes in fair value of contingent consideration

The following table presents the change in fair value of the contingent consideration for the three months ended March 31, 2020.


	Acquisition-
	related
	Contingent
	Consideration
Liabilities:
Balance at December 31, 2019	$	2,430,000
Change in fair value recorded in earnings		30,000
Balance at March 31, 2020	$	2,460,000

XML 33 R21.htm IDEA: XBRL DOCUMENT

Indefinite-lived Intangible Assets and Goodwill (Tables)

3 Months Ended

Mar. 31, 2020

Indefinite-lived Intangible Assets and Goodwill

Schedule of IPR&D asset


	Indefinite-lived
	Intangible Asset
CRV431 balance at December 31, 2019	$	3,190,000
Change in fair value during the three months ended March 31, 2020		—
CRV431 balance at March 31, 2020	$	3,190,000

Schedule of roll-forward of goodwill balance


	Amount
Goodwill balance at December 31, 2019	$	1,870,924
Changes during the three months ended March 31, 2020		—
Goodwill balance at March 31, 2020	$	1,870,924

XML 34 R22.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2020

Accrued Liabilities

Schedule of accrued liabilities


	March 31,		December 31,
	2020		2019
Payroll and related costs	$	190,596	$	346,244
Research and development		62,781		12,075
Legal fees		1,500		2,354
Accrued taxes		74,357		74,357
Other		83,608		58,606
Total accrued expenses	$	412,842	$	493,636

XML 35 R23.htm IDEA: XBRL DOCUMENT

Accounting for Share-Based Payments (Tables)

3 Months Ended

Mar. 31, 2020

Accounting for Share-Based Payments

Schedule of stock based compensation expense


	Three Months Ended
	March 31,
	2020		2019
General and administrative	$	5,910	$	10,365
Research and development		2,336		7,141
Total stock-based compensation expense	$	8,246	$	17,506

Summary of stock option activity and of changes in stock options outstanding under the Plan


							Weighted				Weighted
							Average				Average
	Number of	Exercise Price					Exercise Price		Intrinsic		Remaining
	Options	Per Share					Per Share		Value		Contractual Term
Balance outstanding, December 31, 2019	41,271	$	3.24	-	$	2,452.80	$	194.83	$	43,182	8.42	years
Granted	—		—	-	$	—	$	—	$	—
Forfeited	—		—		$	—	$	—		—
Cancelled	—	$	—	-	$	—	$	—		—
Balance outstanding, March 31, 2020	41,271	$	3.24	-	$	2,452.80	$	209.07	$	—	8.33	years
Vested awards and those expected to vest at March 31, 2020	39,913	$	3.24	-	$	2,452.80	$	216.06	$	—	8.30	years
Vested and exercisable at March 31, 2020	14,415	$	3.24	-	$	2,452.80	$	586.07	$	—	6.52	years

XML 36 R24.htm IDEA: XBRL DOCUMENT

Loss per Share (Tables)

3 Months Ended

Mar. 31, 2020

Loss per Share

Schedule of computation of basic and diluted net loss per share



	Three Months Ended
	March 31,
Basic and diluted net (loss) income per common share	2020		2019
Numerator:
Net loss	$	(4,226,617)	$	(1,983,711)
Preferred stock deemed dividend		—		(24,321)
Net loss attributable to common stockholders	$	(4,226,617)	$	(2,008,032)
Denominator:
Weighted average common shares outstanding		4,345,699		250,126
Net loss per share of common stock—basic and diluted	$	(0.97)	$	(8.03)

Schedule of outstanding securities excluded from the computation of diluted weighted shares outstanding



	Three Months Ended
	March 31,
	2020	2019
Common shares issuable upon conversion of Series A preferred stock	3,184	3,184
Common shares issuable upon conversion of Series C preferred stock	16,839	17,770
Stock options	41,271	9,013
Warrants – liability classified	107,998	107,998
Warrants – equity classified	2,428,568	3,991
Total	2,597,860	141,956

XML 37 R25.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2020

Commitments and Contingencies

Schedule of future minimum rental payments under the Company's noncancelable operating leases


2020	$	210,255
2021		282,176
2022		267,425
2023		53,902
2024 and thereafter		—
Total		813,758
Present value adjustment		(68,283)
Lease liability at March 31, 2020	$	745,475

XML 38 R26.htm IDEA: XBRL DOCUMENT

Business Overview (Details) - USD ($)	1 Months Ended		3 Months Ended
Business Overview (Details) - USD ($)	Oct. 31, 2018	Jun. 30, 2016	Mar. 31, 2019
Business Overview
Fair value of shares issued			$ 126,094
Ciclofilin
Business Overview
First milestone payment	$ 1,000,000
Number of shares issued	1,439
Issuance of common stock in conjunction with milestone payment	$ 55,398
Percentage of issued and outstanding	2.50%	2.50%

XML 39 R27.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Going Concern - Reverse Stock Split (Details)	May 28, 2019
Basis of Presentation and Going Concern
Stock split ratio	0.0142857

XML 40 R28.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Going Concern - Going Concern (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Going Concern
Cash	$ 16,047,669		$ 13,922,972
Net cash used in operating activities	(4,677,962)	$ (2,058,427)
Net loss	(4,226,617)	$ (1,983,711)
Accumulated deficit	(87,409,247)		$ (83,182,630)
Working capital	$ 15,800,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

XML 41 R29.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Going Concern - PPP Loan (Details) - Forecast - PPP Loan	Apr. 13, 2020 USD ($)
Debt
Principal amount	$ 176,585
Interest rate (as percent)	0.98%

XML 42 R30.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Cash (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Summary of Significant Accounting Policies
Cash	$ 16,047,669	$ 13,922,972

XML 43 R31.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Derivative financial instruments (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Derivative Financial Instruments
Derivative financial instruments, at estimated fair value—warrants	$ 15,303	$ 5,623
Level 3 \| Warrants
Derivative Financial Instruments
Derivative financial instruments, at estimated fair value—warrants	$ 15,303	$ 5,623

XML 44 R32.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Property, equipment and depreciation (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Property, equipment and depreciation
Property and equipment, net	$ 48,445		$ 57,166
Depreciation and amortization	6,527	$ 4,641
Carrying value adjustments	$ 0		$ 0
Minimum
Property, equipment and depreciation
Estimated useful life	3 years
Maximum
Property, equipment and depreciation
Estimated useful life	5 years

XML 45 R33.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Goodwill and In-Process Research and Development (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Summary of Significant Accounting Policies
Impairment on goodwill	$ 0	$ 0
Impairment of IPR&D	$ 0	$ 0

XML 46 R34.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Income Taxes (Details) $ in Millions	1 Months Ended
	Apr. 30, 2019 USD ($)
Income Taxes
Net operating loss tax credits	$ 1.0

XML 47 R35.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Research and Development (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Research and Development
Prepaid research and development costs	$ 1.1	$ 0.4

XML 48 R36.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Segment Information (Details)	3 Months Ended
	Mar. 31, 2020 segment
Summary of Significant Accounting Policies
Number of operating segments	1

XML 49 R37.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Derivative Liability - Warrants - Preferred stock, Common Stock and Warrant Offering (Details) - Series A - shares	26 Months Ended
	Sep. 30, 2018	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, Common Stock and Warrant Offering
Preferred shares converted (in shares)	1,200,000
Stock issued as a result of conversion (in shares)	3,000,000	0	0

XML 50 R38.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Derivative Liability - Warrants - Series C Preferred Stock Issuances and Beneficial Conversion Feature (Details)		3 Months Ended		12 Months Ended
	Jul. 03, 2018 USD ($) $ / shares shares	Mar. 31, 2020 USD ($) item $ / shares shares	Mar. 31, 2019 shares	Dec. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) shares
Preferred stock, Common Stock and Warrant Offering
Deemed dividend \| $				$ 77,721	$ 4,700,000
Warrants
Preferred stock, Common Stock and Warrant Offering
Warrants issued (in shares)	88,928
Common Stock
Preferred stock, Common Stock and Warrant Offering
Issuance of stock (in shares)		2,311,867
Conversion of preferred stock to common (in shares)			424
Stock issued as a result of conversion (in shares)				1,353	81,585
Over-Allotment Option
Preferred stock, Common Stock and Warrant Offering
Fair value of warrants \| $	$ 200,000
Series C
Preferred stock, Common Stock and Warrant Offering
Preferred stock issued (in shares)		1,827		1,827
Stock Issuance Costs \| $					$ 500,000
Convertible preferred stock, par value \| $ / shares	$ 1,000	$ 1,000		$ 1,000
Issuance of stock (in shares)	10,826
Consecutive trading days \| item		10
Proceeds from issuance of preferred stock \| $	$ 9,900,000
Offering costs \| $	$ 900,000
Redemption price per warrant \| $ / shares	$ 0.70
Required common stock price to redeem warrants \| $ / shares	434.00
Beneficial conversion amount accreted back as preferred stock \| $		$ 3,800,000			$ 3,800,000
Preferred shares converted (in shares)				147
Conversion of preferred stock to common (in shares)					8,852
Percentage of preferred stock convertible immediately					100.00%
Series C \| Warrants
Preferred stock, Common Stock and Warrant Offering
Exercise price per share \| $ / shares	$ 108.50
Series C \| Preferred Stock
Preferred stock, Common Stock and Warrant Offering
Preferred stock issued (in shares)	1
Conversion of preferred stock to common (in shares)			(46)
Series C \| Over-Allotment Option
Preferred stock, Common Stock and Warrant Offering
Warrants offered placement fee	3,991
Stock price \| $ / shares	$ 119.70
Fair value of warrants \| $	$ 100,000
Series C \| Over-Allotment Option \| Warrants
Preferred stock, Common Stock and Warrant Offering
Fair value of warrants \| $	$ 100,000

XML 51 R39.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Derivative Liability - Warrants - Common Stock and Warrant Offering (Details)	Apr. 25, 2017 USD ($) $ / shares shares	Apr. 04, 2016 USD ($) $ / shares shares	Oct. 13, 2015 USD ($) $ / shares shares	Mar. 31, 2020 USD ($) $ / shares	Dec. 31, 2019 USD ($) $ / shares
Common Stock and Warrant Offering
Derivative financial instruments, at estimated fair value-warrants				$ 15,303	$ 5,623
Level 3 \| Warrants
Common Stock and Warrant Offering
Derivative financial instruments, at estimated fair value-warrants				$ 15,303	$ 5,623
October 13 2015
Common Stock and Warrant Offering
Issuance of stock (in shares) \| shares			8,929
Fixed combined price (in dollars per share) \| $ / shares			$ 1,680
Proceeds from issuance of stock			$ 15,000,000
Offering costs			1,500,000
Additional proceeds if warrants exercised in full			$ 12,800,000
Price of Hepion common stock \| $ / shares				$ 1.77	$ 5.36
October 13 2015 \| Expected warrant term (years)
Common Stock and Warrant Offering
Measurement input				0.53	0.78
October 13 2015 \| Risk-free interest rate
Common Stock and Warrant Offering
Measurement input				0.33	1.66
October 13 2015 \| Expected volatility
Common Stock and Warrant Offering
Measurement input				144	72
October 13 2015 \| Warrants
Common Stock and Warrant Offering
Warrants issued (in shares) \| shares			5,357
Exercise period for warrants			5 years
Exercise price per share \| $ / shares			$ 2,380.00
Fundamental transaction period			90 days
October 13 2015 \| Level 3
Common Stock and Warrant Offering
Derivative financial instruments, at estimated fair value-warrants			$ 4,400,000
April 4 2016
Common Stock and Warrant Offering
Issuance of stock (in shares) \| shares		8,803
Fixed combined price (in dollars per share) \| $ / shares		$ 795.20
Proceeds from issuance of stock		$ 7,000,000
Offering costs		700,000
Additional proceeds if warrants exercised in full		$ 4,200,000
Price of Hepion common stock \| $ / shares				$ 1.77	$ 5.36
April 4 2016 \| Expected warrant term (years)
Common Stock and Warrant Offering
Measurement input				1.01	1.26
April 4 2016 \| Risk-free interest rate
Common Stock and Warrant Offering
Measurement input				0.33	1.66
April 4 2016 \| Expected volatility
Common Stock and Warrant Offering
Measurement input				130.00	75.00
April 4 2016 \| Warrants
Common Stock and Warrant Offering
Warrants issued (in shares) \| shares		4,401
Exercise period for warrants		5 years
Exercise price per share \| $ / shares		$ 952.00
Fundamental transaction period		90 days
April 4 2016 \| Level 3 \| Warrants
Common Stock and Warrant Offering
Derivative financial instruments, at estimated fair value-warrants		$ 1,500,000
April 25 2017
Common Stock and Warrant Offering
Issuance of stock (in shares) \| shares	21,429
Fixed combined price (in dollars per share) \| $ / shares	$ 560.00
Proceeds from issuance of stock	$ 12,000,000
Offering costs	$ 500,000
Fundamental transaction period	90 days
Additional proceeds if warrants exercised in full	$ 7,500,000
Price of Hepion common stock \| $ / shares				$ 1.77	$ 5.36
April 25 2017 \| Expected warrant term (years)
Common Stock and Warrant Offering
Measurement input				2.06	2.31
April 25 2017 \| Risk-free interest rate
Common Stock and Warrant Offering
Measurement input				0.33	1.66
April 25 2017 \| Expected volatility
Common Stock and Warrant Offering
Measurement input				117	69
April 25 2017 \| Warrants
Common Stock and Warrant Offering
Warrants issued (in shares) \| shares	10,714
Exercise period for warrants	5 years
Exercise price per share \| $ / shares	$ 700.00
April 25 2017 \| Level 3 \| Warrants
Common Stock and Warrant Offering
Derivative financial instruments, at estimated fair value-warrants	$ 4,000,000
July 3 2018
Common Stock and Warrant Offering
Price of Hepion common stock \| $ / shares				$ 1.77	$ 5.36
July 3 2018 \| Expected warrant term (years)
Common Stock and Warrant Offering
Measurement input				3.25	3.50
July 3 2018 \| Risk-free interest rate
Common Stock and Warrant Offering
Measurement input				0.33	1.66
July 3 2018 \| Expected volatility
Common Stock and Warrant Offering
Measurement input				116	65

XML 52 R40.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Derivative Liability - Warrants - Components of changes (Details) - Warrants	3 Months Ended
	Mar. 31, 2020 USD ($) shares
Number of Warrants Outstanding
Balance at the beginning of the period (in shares) \| shares	107,998
Balance at end of period (in shares) \| shares	107,998
Level 3
Derivative Instrument Liability
Balance at the beginning of the period	$ 5,623
Change in fair value of warrants	9,680
Balance at end of period	$ 15,303

XML 53 R41.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Derivative Liability - Warrants - Common Stock Offering (Details) - USD ($)				3 Months Ended
	Apr. 30, 2020	Mar. 27, 2020	Feb. 12, 2020	Mar. 31, 2020	Dec. 31, 2019
Controlled equity offering sales agreement
Common stock, par value				$ 0.0001	$ 0.0001
Proceeds from issuance of stock				$ 6,788,465
Sales Agreement
Controlled equity offering sales agreement
Common stock, par value			$ 0.0001
Maximum aggregate offering price		$ 4,600,000	$ 7,000,000
Issuance of stock (in shares)				2,311,867
Proceeds from issuance of stock				$ 6,800,000
Forecast
Controlled equity offering sales agreement
Issuance of stock (in shares)	5,262,806
Proceeds from issuance of stock	$ 11,300,000
Forecast \| Sales Agreement
Controlled equity offering sales agreement
Issuance of stock (in shares)	2,950,939
Proceeds from issuance of stock	$ 4,500,000

XML 54 R42.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details)	1 Months Ended		3 Months Ended
Fair Value Measurements (Details)	Oct. 31, 2018 USD ($) shares	Jun. 30, 2016	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)	Jun. 10, 2016 $ / shares
Fair value measurements
Contingent consideration			$ 2,460,000		$ 2,430,000
Change in fair value of contingent consideration
Change in fair value of contingent consideration			30,000	$ 100,000
Discount rate
Change in fair value of contingent consideration
Measurement Input						6.5
Share Price
Change in fair value of contingent consideration
Measurement Input \| $ / shares						19.60
Ciclofilin
Change in fair value of contingent consideration
Payment of contingent consideration milestone	$ 1,000,000
Number of shares issued \| shares	1,439
Issuance of common stock in conjunction with milestone payment	$ 55,398
Percentage of issued and outstanding	2.50%	2.50%
Level 3 \| Contingent Consideration
Change in fair value of contingent consideration
Balance at beginning of the period			2,430,000
Change in fair value recorded in earnings			30,000
Balance at end of the period			2,460,000
Recurring basis
Fair value measurements
Contingent consideration			2,460,000		2,430,000
Derivative liabilities related to warrants			15,303		5,623
Recurring basis \| Level 3
Fair value measurements
Contingent consideration			2,460,000		2,430,000
Derivative liabilities related to warrants			$ 15,303		$ 5,623

XML 55 R43.htm IDEA: XBRL DOCUMENT

Indefinite-lived Intangible Assets and Goodwill - IPR&D (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Indefinite-lived Intangible Assets and Goodwill
In-process research and development, beginning balance	$ 3,190,000
In-process research and development, ending balance	3,190,000
Impairment losses on IPR&D	$ 0	$ 0

XML 56 R44.htm IDEA: XBRL DOCUMENT

Indefinite-lived Intangible Assets and Goodwill - Goodwill (Details)	Mar. 31, 2020 USD ($)
Roll-forward of goodwill balance
Beginning balance	$ 1,870,924
Ending balance	$ 1,870,924

XML 57 R45.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Accrued Liabilities
Payroll and related costs	$ 190,596	$ 346,244
Research and development	62,781	12,075
Legal fees	1,500	2,354
Accrued taxes	74,357	74,357
Other	83,608	58,606
Total accrued expenses	$ 412,842	$ 493,636

XML 58 R46.htm IDEA: XBRL DOCUMENT

Accounting for Share-Based Payments - Equity Incentive Plan (Details) - USD ($)		3 Months Ended
	Jun. 03, 2013	Mar. 31, 2020	Mar. 31, 2019	Feb. 21, 2018	Dec. 14, 2016	Dec. 02, 2014
Stock based compensation expense
Stock-based compensation expense		$ 8,246	$ 17,506
Equity Incentive Plan
Accounting for Shared-Based Payments
Vesting period (in years)	3 years
Contractual term	10 years
Authorized shares (in shares)				40,535	13,750	11,607
Available shares (in shares)		0
Stock based compensation expense
Stock-based compensation expense		$ 8,246	17,506
General and administrative \| Equity Incentive Plan
Stock based compensation expense
Stock-based compensation expense		5,910	10,365
Research and development \| Equity Incentive Plan
Stock based compensation expense
Stock-based compensation expense		$ 2,336	$ 7,141

XML 59 R47.htm IDEA: XBRL DOCUMENT

Accounting for Share-Based Payments - Activity (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Number of Options
Granted (in shares)	0	0
Stock options
Number of Options
Balance outstanding at the beginning of the period (in shares)	41,271
Balance outstanding at the end of the period (in shares)	41,271		41,271
Vested awards and those expected to vest at the end of the period (in shares)	39,913
Vested and exercisable at the end of the period (in shares)	14,415
Weighted Average Exercise Price Per Share
Balance outstanding (in dollars per share)	$ 209.07		$ 194.83
Vested awards and those expected to vest at the end of the period (in dollars per share)	216.06
Vested and exercisable at the end of the period (in dollars per share)	$ 586.07
Intrinsic Value
Balance outstanding at the beginning of the period (in dollars)	$ 43,182
Balance outstanding at the end of the period (in dollars)			$ 43,182
Weighted Average Remaining Contractual Term (in years)
Balance outstanding term (in years)	8 years 3 months 29 days		8 years 5 months 1 day
Vested awards and those expected to vest at the end of the period (in years)	8 years 3 months 18 days
Vested and exercisable at the end of the period (in years)	6 years 6 months 7 days
Unrecognized compensation cost related to non-vested stock options outstanding
Unrecognized compensation cost related to non-vested stock (in dollars)	$ 100,000
Weighted average remaining vesting period over which unrecognized compensation is expected to be recognized	2 years 8 months 12 days
Stock options \| Minimum
Exercise Price Per Share
Exercise price, low end of the range (in dollars per share)	$ 3.24		$ 3.24
Stock options \| Maximum
Exercise Price Per Share
Exercise price, high end of the range (in dollars per share)	$ 2,452.80		$ 2,452.80

XML 60 R48.htm IDEA: XBRL DOCUMENT

Accounting for Share-Based Payments - Assumptions (Details)		3 Months Ended				12 Months Ended
	Apr. 01, 2016	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2016
Weighted-average assumptions to determine fair value of stock option awards
Actual forfeiture rate (as a percent)		3.00%	3.00%	3.00%	10.00%	3.00%
Estimated future unvested option forfeitures (as a percent)	10.00%

XML 61 R49.htm IDEA: XBRL DOCUMENT

Loss per Share (Details) - USD ($)	3 Months Ended
Loss per Share (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Numerator:
Net loss	$ (4,226,617)	$ (1,983,711)
Preferred stock deemed dividend		(24,321)
Net loss attributable to common shareholders	$ (4,226,617)	$ (2,008,032)
Denominator:
Weighted average common shares outstanding (in shares)	4,345,699	250,126
Net loss per share of common stock-basic and diluted (in dollars per share)	$ (0.97)	$ (8.03)
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)	2,597,860	141,956
Series A
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)	3,184	3,184
Series C
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)	16,839	17,770
Stock options
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)	41,271	9,013
Warrants – liability classified
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)	107,998	107,998
Warrants
Securities excluded from the computation of diluted weighted shares outstanding
Anti-dilutive securities (in shares)	2,428,568	3,991

XML 62 R50.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Contractual Obligations (Details)	Oct. 31, 2019	May 31, 2018	Dec. 31, 2017
Corporate office space
Contractual Obligations
Renewal term (in years)			5 years
Office equipment
Contractual Obligations
Term (in years)		3 years
Office and research laboratory
Contractual Obligations
Term (in years)	3 years

XML 63 R51.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Leases (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Jan. 01, 2019
Lessee, Lease, Description [Line Items]
Operating lease liability	$ 745,475
ROU assets	724,916	$ 797,913
Current lease liabilities	273,093	266,696
Non-current lease liabilities	$ 472,382	$ 540,751
Estimated incremental borrowing rate (as a percent)	6.50%
ASU 2016-02
Lessee, Lease, Description [Line Items]
Operating lease liability			$ 800,000
ROU assets			$ 800,000

XML 64 R52.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Future minimum rental payments under the Company's noncancelable operating leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases
Rent expense	$ 100,000	$ 100,000
Weighted average remaining term (in years)	2 years 10 months 17 days
Future minimum rental payments
2020	$ 210,255
2021	282,176
2022	267,425
2023	53,902
Total	813,758
Present value adjustment	(68,283)
Lease liability at March 31, 2020	$ 745,475

EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 172 299 1 false 41 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.hepion.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.hepion.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.hepion.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.hepion.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Changes in Stockholders??? Equity Sheet http://www.hepion.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity Condensed Consolidated Statements of Changes in Stockholders??? Equity Statements 5 false false R6.htm 00400 - Statement - Consolidated Statements of Cash Flows Sheet http://www.hepion.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - Business Overview Sheet http://www.hepion.com/role/DisclosureBusinessOverview Business Overview Notes 7 false false R8.htm 10201 - Disclosure - Basis of Presentation and Going Concern Sheet http://www.hepion.com/role/DisclosureBasisOfPresentationAndGoingConcern Basis of Presentation and Going Concern Notes 8 false false R9.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10401 - Disclosure - Recent Accounting Pronouncements Sheet http://www.hepion.com/role/DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements Notes 10 false false R11.htm 10501 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrants Stockholders' Equity and Derivative Liability - Warrants Notes 11 false false R12.htm 10601 - Disclosure - Fair Value Measurements Sheet http://www.hepion.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 10701 - Disclosure - Indefinite-lived Intangible Assets and Goodwill Sheet http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwill Indefinite-lived Intangible Assets and Goodwill Notes 13 false false R14.htm 10801 - Disclosure - Accrued Liabilities Sheet http://www.hepion.com/role/DisclosureAccruedLiabilities Accrued Liabilities Notes 14 false false R15.htm 10901 - Disclosure - Accounting for Share-Based Payments Sheet http://www.hepion.com/role/DisclosureAccountingForShareBasedPayments Accounting for Share-Based Payments Notes 15 false false R16.htm 11001 - Disclosure - Loss per Share Sheet http://www.hepion.com/role/DisclosureLossPerShare Loss per Share Notes 16 false false R17.htm 11101 - Disclosure - Commitments and Contingencies Sheet http://www.hepion.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 30503 - Disclosure - Stockholder???s Equity and Derivative Liability - Warrants (Tables) Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrantsTables Stockholder???s Equity and Derivative Liability - Warrants (Tables) Tables 19 false false R20.htm 30603 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.hepion.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.hepion.com/role/DisclosureFairValueMeasurements 20 false false R21.htm 30703 - Disclosure - Indefinite-lived Intangible Assets and Goodwill (Tables) Sheet http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwillTables Indefinite-lived Intangible Assets and Goodwill (Tables) Tables http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwill 21 false false R22.htm 30803 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.hepion.com/role/DisclosureAccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.hepion.com/role/DisclosureAccruedLiabilities 22 false false R23.htm 30903 - Disclosure - Accounting for Share-Based Payments (Tables) Sheet http://www.hepion.com/role/DisclosureAccountingForShareBasedPaymentsTables Accounting for Share-Based Payments (Tables) Tables http://www.hepion.com/role/DisclosureAccountingForShareBasedPayments 23 false false R24.htm 31003 - Disclosure - Loss per Share (Tables) Sheet http://www.hepion.com/role/DisclosureLossPerShareTables Loss per Share (Tables) Tables http://www.hepion.com/role/DisclosureLossPerShare 24 false false R25.htm 31103 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.hepion.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.hepion.com/role/DisclosureCommitmentsAndContingencies 25 false false R26.htm 40101 - Disclosure - Business Overview (Details) Sheet http://www.hepion.com/role/DisclosureBusinessOverviewDetails Business Overview (Details) Details http://www.hepion.com/role/DisclosureBusinessOverview 26 false false R27.htm 40201 - Disclosure - Basis of Presentation and Going Concern - Reverse Stock Split (Details) Sheet http://www.hepion.com/role/DisclosureBasisOfPresentationAndGoingConcernReverseStockSplitDetails Basis of Presentation and Going Concern - Reverse Stock Split (Details) Details 27 false false R28.htm 40202 - Disclosure - Basis of Presentation and Going Concern - Going Concern (Details) Sheet http://www.hepion.com/role/DisclosureBasisOfPresentationAndGoingConcernGoingConcernDetails Basis of Presentation and Going Concern - Going Concern (Details) Details 28 false false R29.htm 40203 - Disclosure - Basis of Presentation and Going Concern - PPP Loan (Details) Sheet http://www.hepion.com/role/DisclosureBasisOfPresentationAndGoingConcernPppLoanDetails Basis of Presentation and Going Concern - PPP Loan (Details) Details 29 false false R30.htm 40301 - Disclosure - Summary of Significant Accounting Policies - Cash (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails Summary of Significant Accounting Policies - Cash (Details) Details http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 30 false false R31.htm 40302 - Disclosure - Summary of Significant Accounting Policies - Derivative financial instruments (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeFinancialInstrumentsDetails Summary of Significant Accounting Policies - Derivative financial instruments (Details) Details 31 false false R32.htm 40303 - Disclosure - Summary of Significant Accounting Policies - Property, equipment and depreciation (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndDepreciationDetails Summary of Significant Accounting Policies - Property, equipment and depreciation (Details) Details 32 false false R33.htm 40304 - Disclosure - Summary of Significant Accounting Policies - Goodwill and In-Process Research and Development (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAndInProcessResearchAndDevelopmentDetails Summary of Significant Accounting Policies - Goodwill and In-Process Research and Development (Details) Details 33 false false R34.htm 40305 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails Summary of Significant Accounting Policies - Income Taxes (Details) Details 34 false false R35.htm 40306 - Disclosure - Summary of Significant Accounting Policies - Research and Development (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails Summary of Significant Accounting Policies - Research and Development (Details) Details 35 false false R36.htm 40307 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details) Sheet http://www.hepion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails Summary of Significant Accounting Policies - Segment Information (Details) Details 36 false false R37.htm 40501 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Preferred stock, Common Stock and Warrant Offering (Details) Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrantsPreferredStockCommonStockAndWarrantOfferingDetails Stockholders' Equity and Derivative Liability - Warrants - Preferred stock, Common Stock and Warrant Offering (Details) Details 37 false false R38.htm 40502 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Series C Preferred Stock Issuances and Beneficial Conversion Feature (Details) Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrantsSeriesCPreferredStockIssuancesAndBeneficialConversionFeatureDetails Stockholders' Equity and Derivative Liability - Warrants - Series C Preferred Stock Issuances and Beneficial Conversion Feature (Details) Details 38 false false R39.htm 40503 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Common Stock and Warrant Offering (Details) Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrantsCommonStockAndWarrantOfferingDetails Stockholders' Equity and Derivative Liability - Warrants - Common Stock and Warrant Offering (Details) Details 39 false false R40.htm 40504 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Components of changes (Details) Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrantsComponentsOfChangesDetails Stockholders' Equity and Derivative Liability - Warrants - Components of changes (Details) Details 40 false false R41.htm 40505 - Disclosure - Stockholders' Equity and Derivative Liability - Warrants - Common Stock Offering (Details) Sheet http://www.hepion.com/role/DisclosureStockholdersEquityAndDerivativeLiabilityWarrantsCommonStockOfferingDetails Stockholders' Equity and Derivative Liability - Warrants - Common Stock Offering (Details) Details 41 false false R42.htm 40601 - Disclosure - Fair Value Measurements (Details) Sheet http://www.hepion.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.hepion.com/role/DisclosureFairValueMeasurementsTables 42 false false R43.htm 40701 - Disclosure - Indefinite-lived Intangible Assets and Goodwill - IPR&D (Details) Sheet http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwillIprDDetails Indefinite-lived Intangible Assets and Goodwill - IPR&D (Details) Details http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwillTables 43 false false R44.htm 40702 - Disclosure - Indefinite-lived Intangible Assets and Goodwill - Goodwill (Details) Sheet http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwillGoodwillDetails Indefinite-lived Intangible Assets and Goodwill - Goodwill (Details) Details http://www.hepion.com/role/DisclosureIndefiniteLivedIntangibleAssetsAndGoodwillTables 44 false false R45.htm 40801 - Disclosure - Accrued Liabilities (Details) Sheet http://www.hepion.com/role/DisclosureAccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.hepion.com/role/DisclosureAccruedLiabilitiesTables 45 false false R46.htm 40901 - Disclosure - Accounting for Share-Based Payments - Equity Incentive Plan (Details) Sheet http://www.hepion.com/role/DisclosureAccountingForShareBasedPaymentsEquityIncentivePlanDetails Accounting for Share-Based Payments - Equity Incentive Plan (Details) Details 46 false false R47.htm 40902 - Disclosure - Accounting for Share-Based Payments - Activity (Details) Sheet http://www.hepion.com/role/DisclosureAccountingForShareBasedPaymentsActivityDetails Accounting for Share-Based Payments - Activity (Details) Details 47 false false R48.htm 40903 - Disclosure - Accounting for Share-Based Payments - Assumptions (Details) Sheet http://www.hepion.com/role/DisclosureAccountingForShareBasedPaymentsAssumptionsDetails Accounting for Share-Based Payments - Assumptions (Details) Details 48 false false R49.htm 41001 - Disclosure - Loss per Share (Details) Sheet http://www.hepion.com/role/DisclosureLossPerShareDetails Loss per Share (Details) Details http://www.hepion.com/role/DisclosureLossPerShareTables 49 false false R50.htm 41101 - Disclosure - Commitments and Contingencies - Contractual Obligations (Details) Sheet http://www.hepion.com/role/DisclosureCommitmentsAndContingenciesContractualObligationsDetails Commitments and Contingencies - Contractual Obligations (Details) Details 50 false false R51.htm 41102 - Disclosure - Commitments and Contingencies - Leases (Details) Sheet http://www.hepion.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails Commitments and Contingencies - Leases (Details) Details 51 false false R52.htm 41103 - Disclosure - Commitments and Contingencies - Future minimum rental payments under the Company's noncancelable operating leases (Details) Sheet http://www.hepion.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderCompanySNoncancelableOperatingLeasesDetails Commitments and Contingencies - Future minimum rental payments under the Company's noncancelable operating leases (Details) Details 52 false false All Reports Book All Reports hepa-20200331.xml hepa-20200331.xsd hepa-20200331_cal.xml hepa-20200331_def.xml hepa-20200331_lab.xml hepa-20200331_pre.xml http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 70 0001558370-20-007863-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-20-007863-xbrl.zip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end